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ABSTRACT: Over the past two decades, the opioid epidemic in the United
States and Canada has evidenced the need for a better understanding of the
molecular mechanisms of medications used to fight pain. Morphine and
fentanyl are widely used in opiate-mediated analgesia for the treatment of
chronic pain. These compounds target the μ-opioid receptor (MOR), a class
A G protein-coupled receptor (GPCR). In light of described higher efficacy
of fentanyl with respect to morphine, we have performed independent μs-
length unbiased molecular dynamics (MD) simulations of MOR complexes
with each of these ligands, including the MOR antagonist naltrexone as a
negative control. Consequently, MD simulations totaling 58 μs have been
conducted to elucidate at the atomic level ligand-specific receptor activity
and signal transmission in the MOR. In particular, we have identified stable
binding poses of morphine and fentanyl, which interact differently with the MOR. Different ligand−receptor interaction landscapes
directly induce sidechain conformational changes of orthosteric pocket residues: Asp1493.32, Tyr1503.33, Gln1262.60, and Lys2355.39.
The induced conformations determine Asp1493.32−Tyr3287.43 sidechain−sidechain interactions and Trp2956.48−Ala2425.46
sidechain−backbone H-bond formations, as well as Met1533.36 conformational changes. In addition to differences in ligand
binding, different intracellular receptor conformational changes are observed as morphine preferentially activates transmembrane
(TM) helices: TM3 and TM5, while fentanyl preferentially activates TM6 and TM7. As conformational changes in TM6 and TM7
are widely described as being the most crucial aspect in GPCR activation, this may contribute to the greater efficacy of fentanyl over
morphine. These computationally observed functional differences between fentanyl and morphine may provide new avenues for the
design of safer but not weaker opioid drugs because it is desirable to increase the safety of medicines without sacrificing their efficacy.
■ INTRODUCTION
Chronic pain is a major public health problem with a high
prevalence and impact on quality of life.1,2 Opiate-mediated
analgesia has shown to be the most efficacious treatment for
chronic pain,3 which primarily targets the μ-opioid receptor
(MOR), a class A G protein-coupled receptor (GPCR)
encoded by the Oprm1 gene.4 Upon binding of opioid
analgesics, ligand-specific conformational changes occur in the
MOR,5 which lead to activation of the receptor and coupling
with intracellular heterotrimeric Gi protein or β-arrestin,
5 thus
mediating the propagation of the receptor message through
different signaling pathways. It remains elusive precisely how
ligand−receptor interactions at the binding site influence
MOR conformational dynamics and hence different signal
transmissions. While the therapeutic effect of opioid analgesics
is mainly attributed to MOR activation through Gi protein
signaling,5−8 their side effects, opioid-induced hyperalgesia,
constipation, respiratory depression, and analgesic tolerance,
have mostly been linked to β-arrestin signaling.5−8 Thus,
agonists biased toward the Gi protein pathway would be ideal
to be considered for drug development as potential future
medications. Following this research direction, high expect-
ations were generated by preclinical in vivo studies on the
MOR Gi protein-biased agonist TRV130 (oliceridine).
9,10
Oliceridine has been recently approved (August 2020) by the
US Food and Drug Administration (FDA) under the trade
name Olinvyk for short-term intravenous use in hospitals and
other controlled settings.11 Moreover, in the prescribing
information leaflet, it is stated that oliceridine is a full opioid
agonist and is relatively selective for the MOR. It is also
recognized that, depending on the dose used, adverse
reactions, including respiratory, and CNS depression may
appear. Importantly, it is also stated that the precise
mechanism of the analgesic action is unknown although
specific CNS opioid receptors are thought to play a role in the
analgesic effects of the drug.12,13 Thus, although drug discovery
programs based on biased agonism seem to be a promising
strategy, in particular for the MOR, they still need further
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knowledge and experimentation both at the molecular and
quantitative pharmacology levels.14−18 In this regard, following
the strategy of MOR biased agonism, several studies have
examined how agonists targeting the MOR interact with
specific residues to selectively regulate coupling of Gi protein
or β-arrestin,19−23 which in some cases have led to the
discovery of new analgesics with reduced negative side
effects.19,24 Yet, although some structural studies of varying
MOR agonist efficacy have been addressed,25,26 there is still a
lack of complete understanding of the precise nature of
ligand−MOR interactions responsible for observed pharmaco-
logical profiles. In this regard, further studies at the atomic
level including agonists with different efficacies can shed light
on MOR activation mechanisms. This was the reason for
selecting morphine and fentanyl for the present study. Fentanyl
is a high-efficacy MOR agonist, whereas morphine is a lower-
efficacy MOR agonist, which, depending on the assay
performed, can behave as a partial agonist.27,28 It is expected
that the generated knowledge can be later incorporated into
drug discovery programs addressed to avoid ligands with
unwanted effects yet conserving the analgesic capacity of the
most powerful drugs.
Biophysical studies of the MOR have led to the
determination of three different crystal structures of the
receptor: inactive,29 activated,5 and fully active30 structures of
the murine MOR (mMOR). In 2012, the inactive crystal
structure of the mMOR29 was obtained by X-ray crystallog-
raphy, co-crystallized with the morphine-like antagonist β-FNA
covalently bound to Lys2335.39 (superscript numbers refer to
the Ballesteros and Weinstein generic numbering scheme31).
This structure provided the first high-resolution insight of the
MOR,29 which enabled the application of structure-based
computational approaches: rational targeted drug design,32−34
receptor oligomerization studies with other GPCRs,35,36 and
study of the mechanism by which sodium ions prevent large-
scale movement of transmembrane (TM) helix 6 away from
TM3, which inhibits receptor activation.37,38 In 2015, an
activated crystal structure of the mMOR bound to the
morphine-like agonist BU-72,5 with intracellular binding of a
G protein mimetic camelid antibody fragment (Nb39), was
resolved by X-ray crystallography.5 G protein mimetic
nanobodies have been shown to be of great utility for
stabilization of active-like states of GPCRs.39−41 The crystal
structure of the activated mMOR shed light on the structural
features of MOR activation that are responsible for the efficacy
of most therapeutic analgesics. In addition, it allowed the
description of an extensive reorganization of the protein−water
polar network, required in the full activation process,5 which is
associated with an efficient allosteric coupling between the
receptor orthosteric pocket and Gi protein-coupling inter-
face.5,42 However, it was not until 2018 that a structure of the
fully active state of the mMOR was achieved by cryo-electron
microscopy.30 This receptor structure with bound peptide
agonist DAMGO and human Gi protein has provided new
insights into the mechanism of intracellular binding to the
MOR.30
Computational techniques such as molecular dynamics
(MD) simulations have shown promise in further under-
standing the complexities of MOR signaling mechanisms. For
example, several MD simulat ion studies of the
MOR,5,7,19,25,26,30 initialized from inactive29 and activated5
mMOR crystal structures, have been worthy in assessing some
relevant features of the activation process. Briefly, the activated
mMOR crystal structure presents, compared to the inactive
crystal structure, (i) large outward movement of TM6 relative
to TM3, (ii) smaller inward movements of TM5 and TM7,
(iii) breakage of the H-bond between Arg1653.50 and
Thr2796.34 (equivalent of the classical Arg3.50−Asp/Glu6.30
GPCR ionic lock, which involves an acidic amino acid at the
position 6.30 that is lacking in the MOR)43 and formation of a
H-bond between Arg1653.50 and Tyr2525.58, (iv) inward
movement of the N7.49PxxY7.53 motif on TM7 toward
TM5,5,7,19,30 and (v) upward axial movement of TM3.44 In
general, previous MD studies were performed by removing
non-native Nb39 and T4 lysozyme, as well as bound ligands
BU-72 and β-FNA, from activated and inactive states of the
mMOR, respectively.5,29,30 In particular, a model was provided
to show how efficacy depends on small chemical differences in
structurally similar morphine-like ligands.5 A common feature
of bound opioid ligands revealed in these studies5,7,19,29,30,45 is
the protonation of their tertiary amine, which is necessary to
form a conserved salt bridge with Asp1473.32 on TM3 in the
orthosteric pocket. This residue is also located within the H-
bond distance with Tyr3267.43 on TM7 in the mMOR,46 thus
favoring interaction between TM3 and TM7 and activation of
the receptor.44,47−49 This can be observed in activated and
inactive crystal structures of the mMOR,5,29 where the distance
between these residues is closer in the activated crystal
structure than in the inactive one. In addition, computational
studies of the mMOR have reported specific protein−ligand
interactions such as the plausible existence of two possible
tautomers of His2976.52, which can have relevance in ligand
function,19 as well as Tyr3267.43 and Gln1242.60 H-bonding
interactions, which may also determine ligand activity.6,46
However, computational techniques are yet to satisfactorily
explain varying MOR agonist efficacy and potency.
Opioid analgesics, the prototypical pain killers, differ from
each other in their structural scaffold and potency. Of all of
them, the naturally occurring compound morphine has been
considered the reference MOR agonist to which other opioid
analgesics are compared.50 In the last decade, fentanyl, a
synthetic opioid 50−100 times more potent than mor-
phine,51−53 and fentanyl analogs have been related to a rapid
increase in the number of opioid overdose deaths because of
legal (such as transdermal patches, which led to an increase in
deaths up to 201054,55) or illicit manufacture.51−53,56,57 This
has contributed to what is called the opioid epidemic, which
has affected mainly the United States and Canada and, in a
lower degree, Europe.58,59 Fentanyl differs from morphine
primarily in its pharmacokinetic properties,50 constituting a
highly lipid-soluble drug compared to low lipid solubility of
morphine, allowing it to penetrate the blood−brain barrier
faster.50,53 Therefore, fentanyl has a faster onset but shorter
duration of action than morphine.50,53 Following receptor
activation, differences in morphine and fentanyl structural
scaffolds determine specific ligand-dependent receptor inter-
nalization processes.60 It has been described60 that high-
efficacy opiates like fentanyl induce rapid MOR phosphor-
ylation and internalization compared to morphine. However,
50−100 times potency difference51−53 between fentanyl and
morphine has been widely discussed by in vitro studies23,61−64
and its potential relation with fentanyl β-arrestin-biased
behavior has not been clearly established. In this regard, a
recent literature65 study supports that both fentanyl and
morphine work as unbiased agonists66−68 toward Gi protein
and β-arrestin signaling pathways.61−63 Apparently, contra-
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dictory conclusions on biased signaling may depend not only
on the variety of biological assays used but also on the
mathematical models and parameters employed. Thus, while
the Emax/EC50 sigmoidal-fitting parameter was chosen in
Figure 1. Crystal and docked ligands. Morphine and fentanyl binding poses. (a) 2D binding poses of respective inactive, activated, and fully active
co-crystallized ligands: β-FNA, BU-72, and DAMGO, and docked ligands of interest: morphine, fentanyl, and naltrexone. (b) 3D conformation of
fentanyl and morphine representative stable binding poses observed during MD simulations (purple and pink, left and right, respectively). Residues
of the hMOR in close contact with fentanyl or morphine (<3.5 Å) are colored in dark green or dark red, respectively. Residues colored in light
green or light red, respectively, are not in close contact but displayed for comparison purposes.
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Vasudevan et al.,65 a comparison between operational τ/KA
and τ parameters was made in Burgueño et al.64 In the latter
study, while fentanyl was found to be G protein-biased under
the τ/KA parameter, an opposite bias toward the β-arrestin
signaling pathway was found when using the τ parameter.64
Moreover, it has been shown, by measuring the antinociceptive
and respiratory depressant effects of some MOR agonists, that
the low intrinsic efficacy of some opioid ligands can explain
their improved side effect profile.69 Additionally, a strong
correlation between measures of efficacy for receptor
activation, G protein coupling, and β-arrestin recruitment
was found for some MOR agonists, including those that had
previously been described as biased.69 A detailed review on the
relationship between agonist efficacy, biased agonism, and
therapeutic window can be bound in Gillis et al.18
From the above data, it can be concluded that the
mechanisms of MOR activation and signal transduction are
not yet fully understood. Although downstream signaling
events occur after a number of steps following the initial drug−
receptor interactions at the receptor binding site, a chemical
connection is expected to be present between initial and final
signaling states. Thus, understanding of the distinct receptor
conformational changes induced by high- and low-efficacy
MOR agonists, and their differential involvement in the
activation of the receptor, can be informative to identify the
structural features that cause different MOR functionalities.
This knowledge is crucial for the rational design of safer but
not weaker drugs.
The experimentally observed functional MOR response to
morphine and fentanyl is a consequence of molecular events
that occur first in the receptor as a result of the interactions
established by these ligands with residues of the receptor
binding pocket, which are then transmitted from the
extracellular to the intracellular side of the cell membrane. In
this context, in the present study, we performed unbiased μs-
length MD simulations to complete a detailed atomic-level
study of the receptor conformational space induced or selected
in the MOR by morphine and fentanyl in order to explain the
variations seen in opiate efficacy.27 Receptor activation by
either induction or selection of receptor active states has been
recurrently under debate70 though they may coexist and be
part of the same thermodynamic cycle.71 Here, both models
are considered, which will allow noteworthy structural
comparisons. In order to understand how opioid analgesics
transmit their molecular signal and generate effects in humans,
we consider it appropriate to perform our study in the native
human MOR (hMOR) and across multiple independent MD
trajectories. Our results show that fentanyl displays a
completely different binding pose from morphine, which
leads to divergent effects on the orthosteric pocket conforma-
tional arrangement. The fact that both morphine and fentanyl
could activate both Gi protein and β-arrestin signaling
pathways raises the question of which signaling pathway
corresponds to the receptor conformational changes found
computationally. This is a question for which there is not a
definite answer with the present knowledge. Nevertheless, to
avoid speculations, structural comparison of computational
structures was made with the current MOR crystal
structures,5,29,30 which are related to the Gi signaling pathway.
Our results show that extracellular conformational changes of
the receptor compromise the ability of its intracellular side to
consistently reach (induce) or maintain (select) the Gi protein-
signaling fully active state.30
■ RESULTS
Homology Models of the hMOR Remain Conforma-
tionally Stable in Control MD Simulations. Native
activated and inactive hMOR homology models were
generated from respective activated and inactive mMOR
crystals5,29 by renumbering sequences, mutating non-con-
served residues, and adding non-crystallized segments of the
inactive hMOR N-terminus, inactive hMOR intracellular loop,
and activated hMOR C-terminus (see Methods). In order to
validate the accuracy of activated and inactive hMOR models,
we performed two control replicas of 2 μs-length unbiased MD
simulations with co-crystallized agonist BU-725 and three
control replicas of 3 μs-length with docked antagonist
naltrexone, respectively. As co-crystallized antagonist β-FNA
of the inactive mMOR29 is covalently bound to Lys2335.39, it is
not an ideal control antagonist for our purposes here, but
because of high similarity between the molecular structures of
naltrexone and β-FNA (Figure 1), β-FNA can be easily
substituted for naltrexone. Therefore, in order to test docking
accuracy, BU-72 was re-docked into our hMOR active model,
while naltrexone was docked into our inactive hMOR model
and compared to co-crystallized β-FNA. Docking results reveal
a top-ranked BU-72 binding pose with a root mean square
deviation (RMSD) of 0.4 Å from its co-crystallized position
and a top-ranked naltrexone binding pose with an RMSD of
0.7 Å compared to the common heavy atoms of co-crystallized
β-FNA. Trajectories of the hMOR with bound BU-72 and
naltrexone show stable receptor conformations (average
RMSDs of 1.8 Å (0.4 SD) and 2.8 Å (0.2 SD), respectively
(Figures S1 and S4)) and ligand binding poses (average
RMSDs of 1.7 Å (0.6 SD) and 2.2 Å (0.6 SD), respectively
(Figures S1 and S2)). These results indicate that both
activated and inactive hMOR models remain near their initial
conformation throughout long-timescale MD trajectories,
which supports their use as reliable starting points to evaluate
the binding effect of ligands of interest: morphine and fentanyl.
Binding Poses of Morphine and Fentanyl Differ. In
order to computationally examine at the atomic level the MOR
efficacy differences between fentanyl and morphine, we first
docked each ligand into our models of activated and inactive
hMOR models. Starting from these protein−ligand systems,
we performed three replicas of 3 μs-length unbiased MD
simulations to allow for ligand-dependent receptor conforma-
tional change. From the respective morphine- and fentanyl-
bound MD trajectories, we identified one stable binding pose
for each ligand (Figure 1), consistent across all replicas and
predominantly selected over other alternative temporary poses
(Figure S2). According to RMSD across MD simulations
(Figure S2), and considering a threshold of ± 2.5 Å to define
ligand stability, we observe that both morphine and fentanyl
are stable after the first microsecond of simulation time and
until the end of each trajectory, independently of the initial
receptor state (average ligand RMSDs of 1.3 Å (0.5 SD) and
2.2 Å (0.5 SD), respectively). Notable initial ligand instability,
limited to the first microsecond of replicas starting from the
receptor activated state with bound fentanyl and replicas #1
and #2 starting from the receptor inactive state with bound
morphine, can be explained by receptor−ligand relaxation and
adaptation (Figure S2). Therefore, both ligands are bound in a
stable fashion, and any differences in ligand stability in the
activated state are probably a result of better fit of the mMOR
crystal structure for morphine-like ligands, as well as
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differences in the molecular scaffold between morphine and
fentanyl (Figure 1). On the other hand, difference of size
between co-crystallized morphine-like ligands of activated5 and
inactive29 mMOR models, BU-72 (smaller) and β-FNA
(larger), respectively, creates a wider orthosteric pocket in
the inactive hMOR model. This may allow ligands larger than
morphine, like fentanyl, to obtain its preferred binding pose
faster in this receptor state. Nevertheless, irrespective of initial
receptor conformation, both morphine and fentanyl reach
consistent stable poses in the orthosteric pocket over replicated
trajectories, which indicate satisfactory docking accuracy
(Figure 1).
Differences are not only observed in the conformation of
morphine and fentanyl but also in orthosteric pocket residues
that are in close contact with them (ligand−residue distance
<3.5 Å). The distribution of residues most frequently making
contact, summarized in Table 1, indicates that morphine
establishes its most stable interactions with the N-terminus,
extracellular regions of TM helix 5, TM6, and TM7, and a
section of TM3 facing TM5 (Figure 1 and Figure S3). On the
other hand, fentanyl establishes more frequent contact with
extracellular loop (ECL) 2, extracellular regions of TM2 and
TM7, and a section of TM3 facing TM2 (Figure 1 and Figure
S3). Interestingly, fentanyl comes into contact with
Cys219ECL2, which is directly involved in an important
structural disulfide bond with Cys1423.25, which may have
implications for conformational change in TM3,72 especially as
this helix has previously been described to undergo an upward
axial movement in receptor activation of class A GPCRs.44,73
In addition to fentanyl and morphine, in the present study, we
have performed three additional replicas of 3 μs-length
unbiased MD simulations with the MOR-bound antagonist
naltrexone starting from the activated hMOR state, which
supports the comparison between morphine and fentanyl.
Naltrexone, similar to morphine and fentanyl, overall maintains
a stable disposition in the binding pocket across replicas
(Figure S2). However, when compared to control replicas
where naltrexone is bound in the inactive hMOR state, it
presents a slightly worse receptor accommodation (average
RMSDs of 2.6 Å compared to 2.2 Å, Figure S2) as might be
expected for its antagonist condition. Similarities between
naltrexone and morphine scaffolds lead to similar interaction
environments (Figure 1 and Table 1). Thus, contact between
naltrexone and the hMOR is similarly and frequently formed
with TM5, TM6, TM7, and a section of TM3 facing TM5
(Table 1 and Figure S3). However, differently from morphine,
naltrexone comes into close contact with Tyr3287.43, a residue
also involved in the interaction between fentanyl and the
receptor in our MD simulations. As these interactions with
Tyr3287.43 are common to both a potent agonist and an
antagonist, it could be speculated that they are apparently
associated with affinity rather than with efficacy. However, a
detailed analysis of the simulations reveals a fine structural
tuning of this residue, which allows the functional distinction
between agonists and antagonists (see below).
Fentanyl and Morphine Induce Different Receptor
Activation Pathways. According to RMSD of the trans-
membrane domain (TMD), the hMOR experiences varying
degrees of backbone conformational change across our MD
simulations (Table S1 and Figure S4). This is an expected
result as the MOR is known to be a highly dynamic
protein,5,7,29,30 as shown when comparing both activated and
inactive crystals5,29 with the fully active crystal structure30
(TMD RMSDs of 1.4 and 3.0 Å, respectively). Making use of a
threshold of ± 3.5 Å, calculated from TMD RMSD of crystal
structures, we quantified the conformational changes between
active and inactive states with respect to either its initial state
or fully active crystal. In general terms, receptor conformation
is relatively stable (≤ 3.5 Å) in all replicas starting from the
activated state with the bound agonist (morphine or fentanyl)
with an average TMD RMSD of 3.2 Å (0.4 SD) from its initial
state and 2.2 Å (0.4 SD) from the fully active crystal30 (Table
S1 and Figure S4). On the contrary, in MD simulations
starting from the inactive state with the bound agonist
(morphine or fentanyl), TMD conformations remain mostly
inactive-like with an average TMD RMSD of 2.8 Å (0.3 SD)
from its initial state and distant (> 3.5 Å) from the fully active
crystal30 (TMD RMSD of 3.6 Å (0.4 SD), Table S1 and Figure
S4). However, the receptor in replicas #2 and #3 with bound
fentanyl or replica #2 with bound morphine starting from the
Table 1. Crystal Ligands, Morphine, Fentanyl, and
Naltrexone Protein−Ligand interactionsa









BU-72 (activated mPro59N‑ter mAsp1473.32
crystal) mLeu1292.65 mTyr3267.43












fentanyl hGln1262.60 (iii) hSer57N‑term




naltrexone hMet1533.36 hAsp1493.32 (i) (ii) (iii)





aResidues in close contact (<3.5 Å) listed with respective murine (m)
or human (h) numbering following the Ballesteros and Weinstein
generic scheme,31 for crystal structures and MD systems, respectively.
Residues interacting with morphine, fentanyl, and naltrexone are
included when frequency of contact is >20% of trajectory time during
at least two MD simulation replicas, independent of the initial state of
the receptor. Similarity between residues in contact across crystals and
MD simulations are labeled as common to the (i) inactive crystal, (ii)
activated crystal, and (iii) fully active crystal.
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inactive state presents occasional TMD RMSDs of 2.8 and 2.9
Å or 2.6 Å from the fully active crystal,30 respectively, which
indicate transient receptor activation toward active-like states
(≤3.5 Å, Figure S4). Larger conformational changes in
simulations starting from the activated state than those starting
from the inactive state are explained by the lack of the
intracellular partner in our models. In more detail, computa-
tional results also suggest that both activated and inactive
crystal structures5,29 (and the models generated from them)
are better adapted to morphine than fentanyl because of the
similarity between morphine and the co-crystallized ligand
scaffolds, which implies that the receptor has to undergo bigger
conformational changes to properly bind fentanyl. TMD
conformational changes can be compared with those observed
when the antagonist naltrexone is bound, where a clear
tendency toward inactivation is observed when starting from
the activated state (average RMSD of 3.9 Å (0.3 SD) from the
initial state, Table S1) and a preservation of the inactive state is
found in control replicas starting from the inactive state
(average RMSD of 2.8 Å (0.2 SD) from the initial state, Table
S1). Surprisingly, when comparing naltrexone-bound receptor
simulations with the fully active crystal,30 the average RMSD
achieved is only 3.0 Å (0.4 SD) or 3.7 Å (0.3 SD) in
trajectories starting from activated or inactive states,
respectively (Table S1). In order to better describe receptor
intracellular conformational changes involved in receptor
activation, four metrics were employed relative to the protein
center, considering only the two last microseconds of MD
simulations: (i) TM3, which moves upward, (ii) intracellular
tips of TM5 and (iii) TM6, which move inward and outward,
respectively; and (iv) NPxxY motif of TM7,43 which rotates
toward the core of the helical bundle. Meanwhile, a fifth metric
was used for assessing intracellular separation between TM3
and TM6: the distance between residues Arg1673.50 and
Thr2816.34 (Arg−Thr), which is equivalent to the ionic lock in
class A GPCRs.43,74−76 Thresholds for these metrics were
based on fully active,30 activated,5 and inactive29 crystal
structures (normalized according to the inactive crystal
structure), with a representative sign, which represents the
movement involved with respect to the receptor center
(inward or outward movement, or downward or upward
movement, “−” or “+” sign, respectively): +0.3 Å for TM3,
−0.8 Å for TM5 and NPxxY, +1.7 Å for TM6, and + 10.0 Å for
Arg−Thr distance as utilized in a previous study.7 These
thresholds were fine-tuned with naltrexone-bound MD
simulation results to classify active- or inactive-like con-
formations of the five intracellular metrics.
Upward axial movement of TM3 (Figures 2 and 3, Table S1,
and Figure S5) is a key indicator of receptor activation, as
shown previously in other GPCRs.77,78 Comparison between
mMOR crystal structures shows that TM3 adopts a more
upward position when the receptor is activated: by distances of
+0.2 Å and +0.6 Å in activated5 and fully active30 crystals with
respect to the inactive one,29 respectively. Based on these
differences and antagonist-bound MD simulations (average
movement of +0.1 Å (0.2 SD) and + 0.3 Å (0.2 SD) in replicas
starting from activated or inactive states, respectively), we
considered a threshold value of +0.3 Å. Our trajectories show
that replicas #2 and #3 starting from the activated hMOR with
bound fentanyl present an average TM3 upward axial
movement of +0.6 Å (0.2 SD), more upward than the initial
receptor activated state and adopting a conformation similar to
the fully active crystal30 (Figure 3, Table S1, and Figure S5). In
replica #1, the receptor maintains an average active-like
position of +0.3 Å (0.2 SD, Figure 3, Table S1, and Figure
S5). In comparison, all replicas starting from the activated state
with bound morphine, despite transient active-like TM3
conformations, show an average less active-like TM3 position
of only +0.2 Å (0.2 SD, Figure 3, Table S1, and Figure S5).
Surprisingly, the tendency observed in replicas starting from
the activated state, where fentanyl selects for more upward
conformations of TM3 than morphine, is not conserved in
replicas starting from the inactive hMOR. Under this
condition, 2/3 trajectories with bound morphine (replicas #1
and #3) induce an active-like average shift of +0.3 Å (0.2 SD),
while replica #2 shows an even larger average of +0.6 Å (0.2
SD), in accordance with the fully active crystal30 (Figure 3,
Table S1, and Figure S5). On the contrary, none of the replicas
starting from the inactive state with bound fentanyl presents
average TM3 movements ≥ +0.3 Å, resulting in mostly
selecting an inactive-like TM3 conformation (Figure 3, Table
S1, and Figure S5). Interestingly, under these conditions,
replica #3 shows a downward TM3 movement of −0.4 Å (0.2
SD, Figure 3, Table S1, and Figure S5), which suggests that the
specific contact fentanyl establishes with Cys219ECL2 does not
reliably invoke TM3 upward axial movement, at least when
starting from the inactive state. Rather, direct interactions
between the ligand and TM3 appear more influential, as
evidenced by the more numerous interactions morphine makes
with TM3 relative to fentanyl. In terms of other TM helices,
the distance between the protein center and intracellular tip of
TM5 (see Methods) decreases in activated5 or fully active
crystal structures30 with respect to the inactive structure29 by
−1.5 Å or −2.1 Å, respectively. Considering these crystal
movements and naltrexone-bound MD simulations (average
movement of +0.5 Å (0.6 SD) and +0.2 Å (0.5 SD) in replicas
starting from activated or inactive states, respectively), a
threshold of −0.8 Å can therefore be established for
determining active- or inactive-like conformations of TM5.
In MD simulations starting from the activated hMOR with
either fentanyl or morphine bound, as expected, TM5 stabilizes
Figure 2. Conformational change of the TM domain in MD
simulations of the inactive hMOR. Extracellular (top) or intracellular
(bottom) views of representative receptor conformations from
replicas #3 and #1 starting from the inactive state with bound
fentanyl (left, in green) or morphine (right, in red), respectively,
compared with the fully active crystal structure (blue).
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(selects) the active-like conformation with normalized
distances mostly between −0.8 Å and − 2.1 Å (Figure 3,
Table S1, and Figure S5). An exception is replica #3 with
bound morphine, where TM5 fails to reliably select an active-
like conformation and instead permits a change toward an
inactive-like conformation with a maximum of +0.7 Å at 2.8 μs
(Figure S5). Likewise, in trajectories starting from the inactive
state with bound fentanyl or morphine, TM5 does not obtain
an active-like conformation and remains inactive (Figure 3,
Table S1, and Figure S5). Moreover, in replica #3, TM5
undergoes an average change of +1.7 Å with a maximum of
+2.9 Å (Figure S5), which places TM5 in a more outward
Figure 3. Intracellular conformation in MD replicas defined by the Arg1673.50−Thr2816.34 distance, vertical TM3 movement, and lateral NPxxY
motif, TM5, and TM6 movements. (a) Structural comparison between the fully active crystal30 (blue) and either activated5 or inactive29 crystals
(top, pink or purple, left or right, respectively), or representative conformation of MD-generated replicas #3 and #1 starting from the inactive state
with bound fentanyl or morphine, respectively (bottom, green or red, left or right, respectively). As a function of time, (b) active- or inactive-like
states of the five different activation-related intracellular features of each replica starting from the activated or inactive hMOR with bound fentanyl,
morphine, or naltrexone (active-like conformations of: Arg1673.50−Thr2816.34, NPxxY, intracellular TM6, intracellular TM5, and TM3, in purple,
green, yellow, orange, or blue, respectively). White gaps represent inactive-like conformations of each respective metric. See the Methods section
for thresholds used to define active- or inactive-like states of intracellular features and Figure S5,S6 for respective metric individual time-dependent
analysis.
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conformation with respect to the receptor core (Figures 2 and
3, Table S1, and Figure S5). This may be the result of an
outward movement of TM6 (see below), which temporarily
influences TM5 through their mutual interhelical contact, an
effect observed in active-like crystal structures.5,30 Exception-
ally, replicas #1 and #2 when morphine is bound in MD
simulations starting from the inactive state present transient or
sustained inward TM5 movement induction with maximum
and average displacements of −1.7 Å and −1.5 Å (0.8 SD),
respectively (Figure S5). Altogether, these results indicate that
TM5 generally remains in an active-like conformation if the
receptor begins in that state, or if initially inactive, morphine is
more effective than fentanyl at inducing active-like con-
formations of TM5 (Figures 2 and 3, Table S1, and Figure S5).
Similarly, activated5 and fully active30 crystal structures present
a more outward TM6 intracellular tip conformation (see
Methods) relative to the inactive crystal,29 with TM6
respectively moving +2.1 Å and +2.0 Å away from the protein
center. Based on these differences and naltrexone-bound MD
simulations (average movement of +0.8 Å (0.5 SD) and +0.6 Å
(0.4 SD) in replicas starting from activated or inactive states,
respectively), a distance threshold of +1.7 Å can therefore be
used for defining active- or inactive-like conformations of
TM6. This helix selects an active-like outward conformation
with an average distance of +3.5 Å (0.6 SD) in trajectories
starting from the activated hMOR, independent of the agonist
bound (Figure 3, Table S1, and Figure S6). However, a
transient deactivation of TM6 occurs when it falls into an
inactive-like conformation in replica #1 with bound morphine
at 1.8 μs, recording a distance of +1.4 Å (Figure S6). Likewise,
in all replicas starting from the inactive hMOR with bound
morphine, TM6 does not demonstrate any outward move-
ment, maintaining only an average distance of +0.4 Å (0.4 SD)
with respect to the inactive crystal and below the +1.7
threshold (Figure 3, Table S1, and Figure S6). However, with
bound fentanyl, active-like conformations of TM6 are induced
in replicas #2 and #3 with maximum values of +2.3 Å and +3.2
Å, respectively (Figures 2 and 3, Table S1, and Figure S6).
While in replica #2 these conformational changes are observed
transiently, a more sustained conformational change occurs in
replica #3 with an average TM6 movement of +1.9 Å (0.6 SD)
over the last microsecond. Altogether, these results indicate
that while both fentanyl and morphine are able to select an
active-like conformation of TM6 in simulations starting from
the activated state, uniquely fentanyl is able to induce TM6
activation when starting from the inactive state, which leads
TM6 to adopt conformations more similar to activated and
fully active crystals5,30 (Figures 2 and 3, Table S1, and Figure
S6). This may represent an indication of the greater efficacy of
fentanyl relative to morphine.
Rearrangement of TM helices during receptor activation
leads to specific intracellular conformational changes such as
the NPxxY motif on TM7 and Arg1673.50−Thr2816.34
interaction (Figure 3). The fully active crystal structure of
the mMOR30 allows a better understanding of the conforma-
tional changes adopted by these regions when the intracellular
Gi protein partner is bound to the receptor. Interestingly, in
the fully active crystal,30 the NPxxY motif adopts an alternative
conformation closer to the inactive crystal structure29 than to
the activated crystal structure.5 This difference may be due to
the non-native binding of Nb39 to the receptor. In these
crystal structures, the NPxxY position can be described
according to the protein center. As such, activated5 and fully
active30 crystals present more inward positions of the NPxxY
motif than the inactive crystal29 (−1.7 and −0.8 Å,
respectively). Consequently, in addition to antagonist-bound
MD simulations (average movement of −0.8 Å (0.6 SD) and
+0.1 Å (0.3 SD) in replicas starting from activated or inactive
states, respectively), a threshold of −0.8 Å can be defined and
applied for determining active- or inactive-like conformations
of this intracellular region (Figure 3, Table S1, and Figure S6).
Because of computational limitations, our MD simulations do
not include bound Gi protein; therefore, it might be expected
that activated-like NPxxY conformations could be selected or
induced over fully active conformations. During MD
simulations starting from the activated state, NPxxY is broadly
selected in its original conformation with an average distance
of −2.5 Å (0.5 SD), independent of the agonist bound (Figure
3, Table S1, and Figure S6). On the other hand, all replicas
starting from the inactive state with bound fentanyl induce a
conformational change so that NPxxY achieves a stable active-
like position (average of −1.4 Å, 0.6 SD), which is the greatest
in replica #3 (average of −1.8 Å, 0.7 SD, Figure 3, Table S1,
and Figure S6). Conversely, when morphine is bound, only
replica #1 starting from the inactive state induces an active-like
position that crosses the −0.8 Å threshold (average of −1.5 Å,
0.3 SD, Figure S6), whereas other replicas select an inactive-
like conformation. These results suggest that fentanyl
consistently induces active-like conformations of both TM7
and the NPxxY motif stronger than morphine (Figure 3). The
intracellular distance between Arg1673.50 and Thr2816.34,
equivalent to the ionic lock in class A GPCRs,43,74−76 can be
classified as being in an active- or inactive-like conformation by
applying a threshold value of +10.0 Å, as used previously.7 The
Arg−Thr distance is broadly selected in its original state in
respective MD simulations starting from activated or inactive
states, independent of the agonist bound, resulting in
respective averages of 13.0 Å (0.9 SD) and 6.5 Å (0.5 SD,
Figure 3, Table S1, and Figure S7). However, in replica #3
when starting from the inactive state with bound fentanyl, this
interaction is seen to transiently break at 1.8 μs when the
distance reaches 10.1 Å (Figure S7). In the replicas where
naltrexone is bound, Arg1673.50 and Thr2816.34 reach and
stabilize distances <10 Å over the entire two last microseconds
of MD simulations, started from either control inactive or
activated states, as expected by the antagonist nature of
naltrexone, contrary to the overall active-like states selected by
agonists when starting from the activated state (Figure 3, Table
S1, and Figure S7). Similarly, naltrexone induces an inward
movement of TM6, in parallel to an outward movement of
TM5 and the NPxxY region, in simulations starting from the
activated state, thus adopting, as expected, inactive-like
conformations of these metrics (Figure 3, Table S1, and
Figure S7). This result indicates that the threshold used clearly
differentiates between active- or inactive-like states of this
interaction. Altogether our results strongly indicate that
receptor activation by means of TM6 outward movement
(Figures 2 and 3, Table S1, and Figure S5-S7) is more
frequently observed with bound fentanyl, which is uniquely
able to initiate in a μs time period, than with morphine.
Therefore, in addition to conformational changes of helical
regions mentioned above, the different frequency of activation
of these intracellular metrics is consistent with the
experimentally observed difference in efficacy between
morphine and fentanyl.
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All these TMs and intracellular metric movements (average
tendencies summarized in Table S1) observed during receptor
(in)activation are indicative of conformational changes at the
intracellular side of the receptor in system dynamics starting
either from activated or inactive states. As shown in Figure 3,
some of these activation features co-exist in time. Therefore,
their simultaneous presence represents a highly active
conformation of the receptor. However, the activation of one
feature prior to another can be an indication of the exploration
of a certain process or pathway of receptor activation. Our
results indicate that all active-like conformational intracellular
metrics are mostly preserved in MD simulations starting from
the activated agonist-bound receptor state, which is biologically
reasonable because morphine and fentanyl are both agonists.
However, agonist-specific differences are consistently observed
during receptor activation from the inactive state. While with
bound morphine, the hMOR largely presents an upward axial
movement of TM3 and exclusively induced TM5 active-like
conformations, with bound fentanyl, the hMOR shows specific
activation of TM6 and stronger activation of the NPxxY motif
on TM7 (Figure 3). Interestingly, replica #3 starting from the
inactive state with bound fentanyl, which most frequently
presents active-like conformations of TM6 and the NPxxY
motif, is the only replica that yields transient active-like
Arg1673.50−Thr2816.34 distances (Figure 3). The non-preser-
vation of this Arg1673.50−Thr2816.34 separation may be a result
of the absence of TM3 upward axial movement, which, in
addition to TM6 outward movement, is required to properly
break intracellular TM3−TM6 interactions. Altogether, these
results are indicative of different receptor activation pathways
induced by morphine (TM3 and TM5) and fentanyl (TM6
and TM7).
It has been widely discussed if fentanyl acts as a β-arrestin
biased agonist or behaves as a balanced agonist.18,23,61−68 As
done for other GPCRs,77,78 we performed a density map
(Figure 4) of the receptor intracellular state achieved
considering two of the main representative intracellular
metrics, which conformationally differ more between morphine
and fentanyl: (i) outward movement of the intracellular side of
TM6 and (ii) conformation of NPxxY with respect to the
protein center. This representation (Figure 4) suggests that in
our MD simulations, we reach a common active-like state with
either fentanyl or morphine bound. It should be considered
that our models starting from the activated hMOR were
modeled from its respective crystal,5 which contains a G
protein mimetic camelid nanobody subsequently removed in
our model. Therefore, the conformations achieved in our
trajectories can be conditioned by the initial crystal used,
which may limit the observations of other alternative
conformations. However, in a timescale of three microseconds,
our simulations have not identified receptor conformational
regions consistent with biased agonism, in agreement with a
Figure 4. Density maps of the outward movement of TM6 and conformation of the NPxxY motif with respect to the protein center. Density maps
of fentanyl or morphine (top or bottom row, respectively) of the three replicas started from activated or inactive states (left or right column,
respectively). Inactive, activated, and fully active crystals are represented for comparison by dark blue, light blue, or green, respectively. Density
maps show conformations more or less frequently induced represented with a hot to cold color gradient.
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recent experimental study.65 It is worth noting that conclusions
on biased agonism from experimental functional studies may
depend on the parameter used for its quantification, where the
proposed ΔΔlog(τ/KA), ΔΔlog(τ), or ΔΔlog(Emax/EC50) bias
factors have led to different biased profiles when applied to
fentanyl, with Gi protein bias, and β-arrestin with and without
bias, respectively.23,65 Interestingly, density maps of simu-
lations starting from the inactive state show that fentanyl
reaches more intermediate intracellular states than morphine,
the latter presenting a larger density closer to the inactive
crystal conformation29 (Figure 4). This result may suppose an
additional indication of the differences in efficacy observed
between both ligands.51−53 On the other hand, the possibility
that the higher trend of fentanyl of generating intermediate
states may facilitate the generation of receptor conformations
more prone to β-arrestin binding is a speculation to be
considered in further studies.
Morphine and Fentanyl Mediate Different Orthos-
teric Pocket Conformational Changes. To ascertain which
conformational changes in the orthosteric pocket, induced or
selected by morphine and fentanyl (see Figure 1), are most
responsible for observed intracellular conformational differ-
ences, we performed an energetic analysis of residues in close
contact with each ligand (Figure S8). Accordingly, from
residues in close contact with both ligands (summarized in
Table 1), fentanyl makes stronger energetic interaction with
Asp56N‑term, Gln1262.60, Cys219ECL2, and Tyr3287.43, whereas
morphine makes stronger interactions with Tyr1503.33 and
Lys2355.39 (Figure S8). Both ligands establish the highly
energetic and conserved MOR-opiate salt bridge with
Asp1493.32, as previously identified in other studies.5,7,19,29,30,45
Figure 5. Orthosteric pocket conformational changes of the hMOR in MD simulations. (a) and (b) Predominant trans (∼180.0°) or cis
conformation (∼300.0°) of (a) Gln1262.60 χ2 dihedral angle or (b) Lys2355.39 χ2 dihedral angle, in representative MD conformations with bound
fentanyl or morphine (purple or pink, hMOR residues in green or red, left and right, respectively). Structural images also show different Asp1493.32
χ1 dihedral angle cis and trans conformations selected, and Asp1493.32−ligand, Tyr1503.33−ligand, or Asp1493.32−Tyr3287.43 H-bond formation. (c)
Conformation frequency of the Asp1493.32 trans χ1 dihedral angle or Gln1262.60 and Lys2355.39 cis χ2 dihedral angle selected with bound fentanyl,
morphine, or naltrexone, independent of the initial state of the receptor (green, red, or purple, respectively). (d) H-bond occupancy of Asp1493.32−
Tyr3287.43, Lys2355.39−ligand, or Tyr1503.33−ligand interaction of simulations with bound fentanyl, morphine, or naltrexone, independent of the
initial state of the receptor (green, red, or purple, respectively). (e) Structural comparison of Met1533.36 conformation between the fully active
crystal30 (blue) and either replica #3 starting from the inactive state with bound morphine or fentanyl (red or green, left or right, respectively). (f)
Frequency of Met1533.36 gauche− conformation in trajectories with bound fentanyl, morphine, or naltrexone, starting from activated or inactive
states (green, red, or purple, respectively).
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From a conformational perspective, we observe (i) H-bonds
(either direct or water-mediated) between the ligand and
Asp1493.32 or Tyr1503.33 and between residues Asp1493.32 and
Tyr3287.43, (ii) specific χ1 dihedral angles of Asp1493.32 and
Met1533.36 (directly determined by conformational changes of
Tyr1503.33), and (iii) specific χ2 dihedral angle selections of
Gln1262.60 and Lys2355.39 sidechains (Figure 5 and Figures
S9−S12). Taking these metrics one by one, morphine and
fentanyl have both been described to make a highly conserved
MOR-opiate electrostatic interaction with Asp1493.32, a residue
located on TM3.5,7,19,29,30,45 In our MD simulations, this
interaction between the ligand and Asp1493.32 is highly
energetically favorable with bound fentanyl but even greater
with bound morphine, independent of the initial receptor state
(average interaction energy of −78.1 or −94.9 kcal/mol,
respectively, Figure S8). Despite this energetic difference
between morphine and fentanyl, both ligands maintain a stable
interaction (<4.5 Å) over three microseconds between their
amine group and Asp1493.32 (Figure 5 and Figure S9). In
addition, Asp1493.32 presents different χ1 dihedral angle
conformations when morphine or fentanyl is bound in the
hMOR (Figure 5 and Figure S9). Two different Asp1493.32
conformations are observable in our MD simulations: (i) a
trans conformation (χ1 dihedral angle >115.0°), predom-
inantly induced in 5/6 trajectories with bound fentanyl
(average frequency of 89.2%, Figure 5 and Figure S9), which
positions the sidechain closer to TM2 and (ii) a gauche−
conformation (χ1 dihedral angle <115.0°) induced by
morphine in all trajectories (average frequency of 93.7%,
Figure 5 and Figure S9), which positions the sidechain away
from TM2. Similar to morphine-bound replicas, when the
antagonist naltrexone is bound to the hMOR, an overall
Asp1493.32 gauche− conformation is induced, independent of
the initial state of the receptor (Figure 5 and Figure S9). Under
this condition, conformational change from gauche− to trans
conformation is only observed in replica #3 starting from the
inactive state at 2.2 μs. As a result of the trans conformation
predominantly observed with bound fentanyl, Asp1493.32 is
within closer H-bonding distance with Tyr3287.43 located on
TM7.46 Activated and fully active crystal structures5,30 show
closer Asp1493.32−Tyr3287.43 interaction distances than the
inactive crystal structure29 (3.2 and 3.4 Å, respectively), and
this interaction also differs in our MD simulations with either
bound morphine or fentanyl (Figure 5 and Figure S9).
Throughout 4/6 trajectories with bound fentanyl, independent
of the initial receptor state, Asp1493.32−Tyr3287.43 maintains a
closer interaction (<4.5 Å) with an H-bond occupancy of
89.5% (36.1 SD, Figure 5 and Figure S9). Conversely, across
all trajectories with bound morphine, only transient
interactions between Asp1493.32 and Tyr3287.43 are observed
with a H-bond occupancy of 24.1% (22.4 SD, Figure 5 and
Figure S9). Similarly, the gauche− conformation overall
selected when naltrexone is bound leads to an Asp1493.32−
Tyr3287.43 H-bond occupancy of 41.1%, independent of the
starting receptor state (19.5 SD, Figure 5 and Figure S9).
These results are supported by the low H-bond occupancy
observed when the antagonist naltrexone is bound into the
orthosteric pocket of the receptor (Asp1493.32−Tyr3287.43 H-
bond occupancy of 41.6% across all replicas, Figure 5), which,
despite being in close contact with Tyr3287.43 like fentanyl,
presents larger Asp1493.32−Tyr3287.43 distances. Therefore,
fentanyl mediates a stronger Asp1493.32−Tyr3287.43 H-bond
than morphine in the orthosteric pocket.
In addition to Asp1493.32−ligand interaction, greater
energetic interactions can also be observed between
Tyr1503.33 and morphine with respect to bound fentanyl
(average potential energy (P.E.) of −5.6 kcal/mol (2.4 SD) or
− 1.9 kcal/mol (2.7 SD), respectively, Figure S8). Differences
in the energetic landscape between fentanyl and morphine
relate to their different scaffold, which presents a single oxygen
group in the former (carbonyl group) and three oxygen groups
in the latter (one ether and two hydroxyl groups, Figure 1).
This distinction translates to a different H-bond occupancy
(either direct or water-mediated) between Tyr1503.33 and
fentanyl or morphine with average occupancies of 32.2% (7.2
SD) or 89.2% (9.4 SD), respectively (Figure 5). In the case of
the antagonist naltrexone, which presents a scaffold similar to
morphine (Figure 1), it adopts a Tyr1503.33−naltrexone H-
bond occupancy of 56.1% (9.6 SD, Figure 5). Tyr1503.33 and
morphine or naltrexone hydroxyl/carbonyl groups are
considered either donors or acceptors when evaluating
Tyr1503.33−ligand H-bond presence/absence. The higher H-
bond occupancy between morphine and Tyr1503.33 enhances
upward axial movement of TM3 (Figure 3, Table S1, and
Figure S5) and exerts a stabilizing effect in the bottom of the
receptor orthosteric pocket, as observed with the conformation
of Met1533.36 (Figure 5 and Figure S10). In MD simulations
starting from the activated state, independent of the agonist
bound, the Met1533.36 χ1 dihedral angle generally adopts a
gauche− conformation (∼60.0°). Likewise, in MD simulations
starting from the inactive state with bound morphine,
Met1533.36 gauche− conformation is selected with a frequency
of 93.2% (8.8 SD, Figure 5 and Figure S10). However, when
fentanyl is bound, alternative conformations of Met1533.36 (χ1
> 90.0°) are more frequently induced with a frequency of
65.3% (4.9 SD, Figure 5 and Figure S10). Interestingly, in
naltrexone-bound conditions, Met1533.36 gauche− conforma-
tion is overall selected only with a frequency of 58.3% (24.5
SD, Figure 5 and Figure S10), which indicates that this residue
conformationally fluctuates more with bound naltrexone than
when fentanyl or morphine is bound in the hMOR, probably as
a result of the direct contact naltrexone makes with this
sidechain (Table 1 and Figure S3). Selection of χ1 gauche−
appears to be associated with aforementioned active-like
conformations of TM3 (Figure 3, Table S1, and Figure S5).
This process can be linked with fentanyl-mediated TM6
activation where the receptor core undergoes reorganization
and becomes more flexible. Once this transition ends, the
stability of the core can be recovered, as indicated by
trajectories starting from the activated state (Figure 5 and
Figure S10). Conversely to the low H-bond occupancy
between fentanyl and Tyr1503.33 in TM3, which conditions
the conformation of Met1533.36, an energetically favorable
interaction with Gln1262.60 on TM2 is established with an
average P.E. of −3.0 kcal/mol (4.4 SD). This contrasts with an
unfavorable average P.E. of +2.7 kcal/mol (2.2 SD) displayed
by morphine (Figure S8). Subsequently, Gln1262.60 shows
conformational differences when morphine or fentanyl is
bound in the hMOR (Figure 5 and Figure S11). In general,
two different Gln1262.60 χ2 dihedral angles are observed in our
MD simulations: (i) a cis and (ii) trans (∼300.0° and ∼ 180.0°,
respectively). By using a threshold of ± 240°, Gln1262.60 can
be categorized according to these two conformations (Figure 5
and Figure S11). Although both conformations are observable
with each ligand, its frequency is noticeably different from one
to another. Systems with bound fentanyl predominantly induce
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the trans conformation 86.0% of the time (10.5 SD, Figure 5
and Figure S11), which positions Gln1262.60 toward the
orthosteric pocket, allowing a three-way sidechain interaction
with Tyr3287.43 and Asp1493.32 and supporting closer Asp−Tyr
interaction (Figure 5 and Figure S13). By contrast, morphine
selects the Gln1262.60 cis conformation with a frequency of
80.5% (13.5 SD, Figure 5 and Figure S11), which positions it
toward the membrane and negatively affects the Asp−Tyr
interaction (Figure 5 and Figure S13). Similar to morphine,
naltrexone selects the Gln1262.60 cis conformation with a
frequency of 87.3% (10.0 SD, Figure 5 and Figure S11).
Finally, Lys2355.39−agonist interaction is the only one
established between morphine and TM5 and is present at
least 20.0% of the time in 5/6 trajectories (Table 1 and Figure
S2). This interaction shows energetic differences between
morphine and fentanyl with an average P.E. of +6.1 kcal/mol
(6.9 SD) or +16.5 kcal/mol (3.8 SD), respectively (Figure S7).
Similar to Tyr1503.33, the Lys2355.39 amino group establishes
an interaction with any of morphine’s oxygen groups (ether,
hydroxyl groups #1 and #2) with a H-bond occupancy of
63.5% (13.2 SD) but generally avoids interaction with
fentanyl’s carbonyl group (H-bond occupancy of 7.2% (6.9
SD), Figure 5 and Figure S12). When naltrexone is bound,
which shares a similar scaffold with morphine (Figure 1),
Lys2355.39 H-bonds naltrexone with an occupancy of 43.9%
(18.6 SD). In this specific interaction, ligand oxygen groups are
only considered as acceptors. Accordingly, Lys2355.39 displays
two different χ2 dihedral angles, either adopting a cis or trans
conformation (∼300.0° or ∼ 180.0°, respectively) where a
threshold of ± 240° can be used to categorize these two
sidechain conformations (Figure 5 and Figure S12).
Independent of the bound ligand, the trans conformation is
the most commonly selected with the sidechain interacting
with the extracellular solvent rather than with the ligand.
However, different rates of cis conformation are induced
between fentanyl, morphine, and naltrexone, with average
percentages of 11.5% (5.1 SD), 38.0% (13.9 SD), and 40.0%
(14.9 SD), respectively (Figure 4 and Figure S12). In this case,
the cis conformation permits interaction with the bound ligand.
This indicates that morphine mediates different conforma-
tional dynamics of Lys2355.39 (Figure S13), which, accordingly,
helps to stabilize the binding pose of morphine inside the
orthosteric pocket of the receptor.
Conformational Changes of Trp2956.48 Inducing
Different Bottom-Orthosteric Pocket Receptor Inter-
actions Are Relevant in TM5−TM6 Packing. During
activation of the MOR, TM6 moves outward, which, together
with conformational rearrangement of TM3, TM5, and TM7,
creates solvation of the intracellular cavity5 and conformational
changes in specific residues on TM6, such as Trp2956.48.5 By
classifying sidechain conformation by dihedral angles, gauche−
(0−120°), trans (120−240°), or gauche+ (240−360°) in
mMOR crystals, Trp2956.48 χ2 changes from gauche− to trans
to gauche+ in inactive, activated, and fully active crystals,
respectively (values of 78.6°, 121.3°, and 342.9°, respectively).
In our MD simulations, we observe two stable Trp2956.48
conformations (Figure 6 and Figure S14): (i) an activated-like
trans conformation at 225.6° (6.9 SD) and (ii) an inactive-like
gauche− conformation at 97.1° (4.1° SD). We do not observe
the gauche+ conformation probably because, due to computa-
tional limitations, we have not included an interacting Gi
protein in our simulations. In all trajectories starting from the
activated hMOR state, independent of the agonist bound, the
Trp2956.48 trans conformation is stabilized within 1250 ns
(Figures 6 and 7 and Figure S14). This enables a novel H-
bond between Trp2956.48 and Ala2425.46 (sidechain amino
group and backbone carbonyl group, respectively) with an
average occupancy of 97.7% (1.1 SD), which is beneficial for
maintaining active conformations of TM5 and TM6 (Figure
7). Conversely, all replicas starting from the inactive state with
bound fentanyl, as well as replicas #2 and #3 where morphine
is bound, select an inactive-like Trp2956.48 gauche− con-
formation (Figure 6 and Figure S14). This conformation
enables H-bonding with the adjacent residue on TM7,
Asn3307.45, which enhances TM6−TM7 interaction and avoids
the interaction of this residue with water molecules, thus
inhibiting TM6 activation (Figure 7). Interestingly, in replica
#1 starting from the inactive state with bound morphine, the
activated-like trans conformation is induced at 400 ns, which is
the only replica in this category where the NPxxY motif yields
an active-like conformation, observed from 200 ns onward
(Figure S6). This enables sidechain−backbone Trp2956.48−
Ala2425.46 H-bonding between TM5−TM6 with an occupancy
of 68.0%, which assists TM5 activation after 500 ns (Figure
S5), even though TM6 activation is not observed. Despite
active-like conformations of the NPxxY motif being present in
all replicas starting from the inactive state with bound fentanyl,
only replica #3 transiently induces the trans conformation of
Trp2956.48 during the first 500 ns before returning to gauche−
(Figure S14). This conformational change results in only 6%
Trp−Ala H-bonding occupancy, but repeated sidechain
Figure 6. Trp2956.48 conformational change in MD simulations with
respect to MOR crystals. Comparison between different conforma-
tions of Trp2956.48 (χ2 dihedral angle represented by spheres) of fully
active, activated, and inactive crystals (salmon, blue and purple,
respectively) and (i) representative MD-generated hMOR conforma-
tions with bound fentanyl (green, middle row) of replica #2 starting
from the activated state, replicas #3 and #2 starting from the inactive
state (from left to right, respectively) or, ii) with bound morphine
(red, bottom row), replica #3 starting from the activated state, or
replicas #1 and #2 starting from the inactive state (from left to right,
respectively).
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switching is enough to trigger the gradual activation of TM6,
which is observed more strongly later in this trajectory (Figure
S6). Indeed, Trp2956.48 and Ala2425.46 mostly interact via
hydrophobic contact for the rest of the trajectory (closest
distance: 4.7 Å, Figure S14) rather than H-bonding because
Trp2956.48 remains in its gauche− conformation. This suggests
that although bound morphine is capable of eliciting similar
conformational changes in Trp2956.48, switching from gauche−
to trans, its effect can be different depending on other residues,
such as Met1533.36. In particular, it is noticeable in replica #3
with bound fentanyl that Met1533.36 χ2 conformational
switching occurs at the same time as Trp2956.48 (Figures S10
and S13) with these switches in Met1533.36 conformation
becoming more frequent as TM6 moves outward. Despite
these differences, closer interactions between Trp2956.48 and
Ala2425.46 are observed with active-like conformations of TM5,
TM6, and the NPxxY motif (Figure 7), which demonstrates
the importance of rearrangements in TM5−TM6 packing. For
comparison purposes, naltrexone-bound trajectories induced
or selected gauche− conformations from respective activated or
inactive states with percentages of 74.6 and 88.8%, respectively,
with the closest Trp2956.48−Ala2425.46 distance of 8.4 Å
achieved in control simulations starting from the inactive state.
This distance, larger than that observed in fentanyl-bound
trajectories, suggests a lack of TM5−TM6 packing, which
favors the inactive state of the receptor. In addition, we observe
different distributions between Asp1493.32−Tyr3287.43 H-
bonding in the orthosteric pocket and Trp2956.48−Ala2425.46
Figure 7. TM5−TM6 interaction in MD simulations: Trp2956.48 and Ala2425.46. MD-generated receptor structures showing the interaction of
Trp2956.48 with Ala2425.46 or Asn3307.45, in (a) replica #3 or #2 starting from inactive or activated states with bound fentanyl or morphine,
respectively (left or right, green or red, respectively) or (b) replica #2 starting from the inactive state with bound fentanyl (green). (c−e) Per
replica average (c) Trp2956.48 χ2 dihedral angle, (d) Trp2956.48−Ala2425.46 distance, and (e) Trp2956.48−Ala2425.46 H-bond occupancy (shades of
green, red, or purple for replicas #1−3 with bound fentanyl, morphine, or naltrexone, respectively).
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.0c00890
J. Chem. Inf. Model. 2021, 61, 1251−1274
1263
interaction, where average Trp−Ala distances of 3.7 Å (1.8
SD) or 6.8 Å (3.0 SD) are reported when the Asp−Tyr H-
bond is formed or broken, respectively (Figure S13). This
demonstrates the interconnectivity of residue−residue inter-
actions in the orthosteric pocket, which may have different
implications for intracellular receptor conformations.
Intracellular Conformational Changes Correlate with
Ligand-Specific Conformational Changes in the Re-
ceptor Orthosteric Pocket. In order to elucidate how
ligand-specific orthosteric pocket conformational changes
determine intracellular receptor conformations, we performed
a number of statistical analyses (Figures S15 and S16) with
respect to (in)activation of specific intracellular receptor
metrics: TM3 upward-, TM5 inward-, TM6 outward-, and
NPxxY motif inward-movement and Arg1673.50−Thr2816.34
distance. The chi-square (chi2) test was chosen to examine
the association between these intracellular metrics and
orthosteric pocket metrics: sidechain−sidechain Asp1493.32−
Tyr3287.43, Lys2355.39− or Tyr1503.33−ligand, sidechain−
backbone Trp2956.48−Ala2425.46 H-bond formation and
Met1533.36 gauche− conformation. The chi2 analyses involve
two-way frequency tables of binary variables (presence/
absence of H-bonds or Met1533.36 gauche− conformation
and active/inactive state of each intracellular metric, Figures
S15 and S16). In addition, the potential association between
the Trp2956.48−Ala2425.46 distance and active- or inactive-like
state of the selected intracellular metrics was measured using
Student’s t-tests (Figure S16). All these statistical analyses were
performed independently of the initial state of the receptor and
the ligand bound. Our objective was not to find differences
between ligands but to detect general mechanistic trends of
receptor activation. Because we are combining data from
different ligands and MD simulations with different starting
states, we should take these tests as exploratory rather than
confirmatory of the tested hypotheses. Nevertheless, the
consistency found in the results suggests these analyses are
valuable to realize the apparent relationships between the
selected structural features. Chi2 tests show that differences
exist between active- and inactive-like intracellular receptor
conformations and Asp1493.32−Tyr3287.43, Tyr1503.33−ligand,
Lys2355.39−ligand, Trp2956.48−Ala2425.46 H-bond formation
and Met1533.36 gauche− conformation (p < 0.05 in all cases,
Figures S15 and S16). The absence of statistical significance
was found for the association between Tyr1503.33−ligand H-
bond formation and the intracellular TM6 state (p = 0.051,
Figure S15) and between Lys2355.39−ligand H-bond formation
and either TM3 or TM5 movements (p = 0.9 or 0.7,
respectively, Figure S15). Interestingly, the fact that this last H-
bond formation is not associated with movements of TM5
(Figure S15) suggests that Lys2355.39 affects the position of the
ligand in the orthosteric pocket, which in turn determines the
conformation of other residues (such as Asp1493.32), rather
than directly transmitting the signal through TM5. Large chi2
values observed in the association between the sidechain−
backbone Trp2956.48−Ala2425.46 H-bond and intracellular
metrics (values between 252.7 and 582.9, which are extremely
significant because 2 × 2 contingency tables contain 1 degree
of freedom and significant P < 0.05 values are reached if chi2 >
3.841, Figure S16) highlight the relevance of this interaction in
the (in)activation of the hMOR. Similarly, Student’s t-tests
show that the Trp2956.48−Ala2425.46 distance statistically
differentiates between active and inactive TM3, TM5, TM6,
and NPxxY motif conformational states and the Arg1673.50−
Thr2816.34 distance state (p < 0.001 in all cases, Figure S16),
showing overall Trp2956.48−Ala2425.46 closer distances in
active- than inactive-like states. Close Trp2956.48−Ala2425.46
distances (see Methods), which are mainly attributed to helical
rearrangement, enhance the establishment of hydrophobic
contact between both residues. These results highlight the
importance of these two residues becoming physically close
irrespective of their H-bonding status.
Altogether, these results indicate that, independent of the
ligand bound and the starting conformation of the receptor for
MD simulations, mostly all orthosteric metrics studied in this
study statistically reveal significant differences between active-
and inactive-like states of the intracellular metrics used, thus
establishing an (in)activation communication connection
mechanism through the entire receptor. The differences
found between agonists in their propensity to select or induce
specific receptor conformations through these mechanistic
structural features may explain the differences in efficacy
observed experimentally.27,51−53
Internal Receptor Polar-Water Network Differs
between Morphine and Fentanyl. A polar network
mediated by water molecules has been described to be
involved in signal transmission from the extracellular to the
intracellular side of the mMOR.5 An average water density
map of the hMOR reveals differences in this network between
activated/inactive states in morphine/fentanyl-bound MD
simulations (Figure 8). As might be expected, the different
molecular size and binding pose of fentanyl compared to
morphine affects the number of water molecules that can enter
Figure 8. Polar water network in MD simulations. Comparison of the
water network connecting extracellular and intracellular sides of the
hMOR with bound fentanyl or morphine (green or orange,
respectively). Receptor conformations from replicas #1 and #1
starting from the activated hMOR (snapshots at 2.4 μs and 3.0 μs,
respectively) with (a) fentanyl and (b) morphine and replicas #3 and
#1 starting from the inactive hMOR (pictures at 2.2 μs and 1.8 μs,
respectively) with (c) fentanyl and (d) naltrexone.
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the orthosteric pocket. Therefore, we observe more waters
when morphine is bound than with fentanyl, independent of
the initial receptor state (Figure 8). In terms of the receptor
core or intracellular regions, two different water clusters can be
identified: (i) between Trp2956.48 and Asn3307.45 on TM6 and
TM7, respectively, and (ii) adjacent to the intracellular
N7.49PxxY7.53 motif on TM7. In MD simulations with bound
fentanyl, greater solvation is observed at both these regions, in
particular near the NPxxY motif, which has previously been
described as important for active conformations of the mMOR
or class A GPCRs, in general.5,79−81 This is consistent with
stabilization of an active-like receptor conformation or receptor
activation from the inactive state, which is observed in replica
#3 with bound fentanyl (Figure 8). On the contrary, with
bound morphine, these same water clusters are less
pronounced, even with greater solvation in the orthosteric
pocket, which suggests comparatively reduced receptor
activation or increased destabilization of the active state.
This is the case even when an active-like trans conformation of
Trp2956.48 is induced, which allows sidechain−backbone H-
bonding with Ala2425.46 (Figure 8), as observed in replica #1
when starting from the inactive state. Furthermore, in this
same replica, despite corresponding activation of the NPxxY
motif (Figure 3), the lack of TM6 conformational change as a
whole allows fewer water molecules to access this region
compared to simulations with bound fentanyl. In the same
direction, when the antagonist naltrexone is bound, solvation
of the two aforementioned regions is reduced even in
simulations starting from the activated state, which facilitates
hydrophobic interactions, TMD rearrangements, and inactiva-
tion of the receptor (Figure 8). This indicates that proper
conformational movements of both TM6, most importantly
through Trp2956.48, and the NPxxY motif are necessary for
formation of a water column in the receptor core, which is
thought to be necessary for activation of the MOR.5,79−81
■ DISCUSSION
The recent spate of deaths from fentanyl and its derived
compounds51−53,56,57 raises special interest in how these high-
efficacy agonists interact with the hMOR compared to lower-
efficacy agonists such as morphine. Questions about potential
differences between morphine- and fentanyl-based signaling
lead to the need for better understanding of how these two
ligands modulate MOR conformation and function and how
this could instigate stronger responses from the receptor51−53
or even stimulate different downstream pathways.25,64 There
are conflicting experimental data about whether fentanyl is a
biased agonist or not. It was proposed through in vitro studies
that fentanyl is more biased toward β-arrestin activation than
morphine,23,25,64 but the recent literature65 did not find
significant bias of neither fentanyl nor a collection of fentanyl
analogues toward Gi protein or β-arrestin signaling pathways.
Interestingly, opposite bias profiles were obtained for fentanyl
depending on the model parameter used for bias quantifica-
tion: Gi protein bias or β-arrestin bias when τ/KA or τ
parameters were respectively chosen.64 MD simulations cannot
give a definite answer to this problem. GPCR-dependent β-
arrestin signaling involves the phosphorylation of particular
serine or threonine residues at the intracellular regions of the
receptor by GPCR kinases (GRKs). In a recent study on the
dopamine D1 receptor,
82 it was found that intracellular loop 3
(ICL3) phosphorylation affects arrestin binding and activation
through various phosphorylation patterns, which direct the
signaling to either one effector or another. This bar-coded
phosphorylation signaling affects indirectly G protein coupling
because arrestin- and G protein-coupled receptor populations
coexist and the increase of one population decreases the
other.82 However, phosphorylation patterns may vary between
GPCRs, in particular for the MOR. For this receptor, it was
found that a single threonine (T180) in ICL2 is fundamental
for agonist-dependent receptor phosphorylation and subse-
quent arrestin binding, activation, and signalling.83 In the
present study, the examination of MD simulations of the
hMOR with either fentanyl or morphine bound did not find
differences with respect to T180. It is worth noting that with
present computational means, it is not possible to assess which
active receptor conformations are more prone to be
phosphorylated, which ultimately lead to β-arrestin signaling.
However, at the timescales and starting models used, our MD
simulations suggest the presence of a single common active-
like receptor state stabilized by both morphine and fentanyl, in
comparison to multiple conformations observed in other
GPCRs such as the adenosine A2A receptor.78 This leads us to
consider an unbiased behavior of both morphine and fentanyl,
where both ligands achieve a common active-like receptor state
by differently activating ligand-specific conformations of the
receptor. Nevertheless, it cannot be completely discarded that
the higher propensity of fentanyl to induce receptor
intermediate states could facilitate the generation of con-
formations predisposed to β-arrestin binding. In addition, it is
worth noting that reliable quantification of biased agonism
needs the use of proper parameters, and in this regard, the
following has been proposed: the use of operational efficacy
(τ) versus the transduction coefficient (τ/KA) in the case of
comparing ligands producing different maximum responses or,
in other words, when partial agonism is present64 or, moreover,
the inclusion of constitutive receptor activity in the
mathematical modeling in those cases where basal receptor
response is observed.17,84 On the contrary, other authors have
applied the Emax/EC50 parameter for bias calculation of μ-
opioid agonists.65 Thus, it may happen that the mathematical
models used for agonist bias quantification, in particular in
those systems where pharmacological complexity either at the
ligand (partial agonism) or receptor (constitutive activity)
levels is present, may have permitted the occurrence of
conflicting results in some cases. Nevertheless, a connection
between functional experimental results yielded by ligands
from particular receptors and the molecular interactions of
these ligands with the residues in the receptor binding pocket
is expected. The observed functional response is a consequence
of molecular events that occur first within the receptor and are
later propagated to the effector system.
The results obtained in this study greatly depend on the
interactions established by morphine and fentanyl in the MOR
orthosteric pocket, which to be properly determined requires a
sufficiently accurate initial docking pose, as has been previously
demonstrated in MD simulations of other GPCR-ligand
complexes.86 In this regard, our accurate docking of co-
crystallized ligands (or their close analogues) gives us reason to
have confidence in our docking protocol. We consider that, in
order to properly characterize the efficacy of fentanyl and
morphine in humans, it is important to study the hMOR
instead of the mMOR, thus avoiding protein−ligand
interactions with non-conserved residues. At the time our
models were generated, only crystals of the activated5 and
inactive29 mMOR were available. Models of activated or
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inactive hMOR states were successfully validated by high
conformational stability in MD simulations of the receptor and
bound control ligands: BU-72 and naltrexone. However, a
third mMOR crystal structure30 was later released, which
details the fully active receptor conformation coupled to
human Gi protein. Despite not providing data of the β-arrestin
signaling pathway, it supposes a novel point of reference for
comparison with our MD simulations in terms of Gi protein
signaling. Therefore, this crystal structure was used as an
independent positive control, which, in addition to the use of
co-crystallized BU-72-bound activated hMOR and naltrexone-
bound inactive hMOR, allows us to quantify different
conformational changes induced or selected in the hMOR by
fentanyl or morphine. The question arises which is the proper
reference state for the system. Both the apo receptor87 and an
antagonist-bound receptor may, in principle, be suitable for
this purpose. We chose the latter condition because of the high
stability of an antagonist-bound inactive receptor state, as well
as the potential to deactivate an active receptor state to the
inactive. However, utilizing the apo receptor to investigate the
apparently low reported basal activity of the hMOR85 is an
interesting area for future study, in particular regarding
potential allosteric modulation by anionic phospholipids as
has been reported for other homologous class A GPCRs.77,78,88
Under the simple framework of the two-state model of
receptor activation: ↔ *R R
L
, with R and R*, the inactive and
active receptor states and L, the interconversion equilibrium
constant L = [R*]/[R], the agonist intrinsic efficacy α can be





through the selection branches: A + R ↔
K
AR and A + R* ←→
αK/
AR* of the thermodynamic cycle, where K is the dissociation
equilibrium constant. Thus, induction and selection ap-
proaches are equivalent in terms of intrinsic efficacy α within
the context of four receptor species in equilibrium. However,
the situation can be more complex when receptor states
include ensembles of protein conformations. Conversion of AR
into AR* may involve different intermediates with different
kinetics. The kinetic component can be a limiting factor in
some cases making more complex the correspondence between
induction and selection approaches. Considering that the
inactive receptor R is, normally, the major species in the
absence of an agonist, it is expected that an agonist making
“easier” the conversion of AR into AR* will reflect this
molecular feature onto its pharmacological profile. Our
simulations suggest that this could be the case in the
comparison between morphine and fentanyl. Therefore, in
the present study, receptor activation by either induction or
selection of receptor active states has been considered. This
has been possible because both inactive and active MOR
structures were available. Therefore, when starting from a
specific simulation initial state (activated or inactive hMOR) if
the receptor achieves the opposite state (inactive- or active-like
conformations, respectively) the induced-fit approach is
followed, otherwise, if the initial state is preserved, we can
state that a selection approach occurs. This makes the dynamic
structural analysis more robust and reliable. It should be taken
into account that because we are using receptor states obtained
for particular ligands, there is a bias toward these states for
those ligands structurally resembling the crystallized ones
(BU72 and β-FNA). In this regard, the morphine binding pose
is widely known42,89,90 because of its similarity with the
morphine-like scaffold of agonist BU-72 and antagonist β-FNA
in the activated or inactive mMOR,5,29 respectively. Con-
versely, the native fentanyl binding pose is still unclear, with
previously proposed binding poses differing in their
orientation,26,90−96 and no consensus having been reached.
Mutagenesis-based studies46,97 first characterized the binding
landscape of fentanyl and fentanyl derivatives involving
Asp1493.32, Tyr1503.33, Asn1523.35, Trp3207.35, His3217.36, and
Tyr3287.43. During the last two decades, the use of computa-
tional techniques has revealed new details in fentanyl binding,
identifying different residues that might potentially inter-
act.25,26,91,96 Despite fentanyl being more prone to change in
its initial conformation during our MD simulations compared
to morphine, the same stable binding mode of fentanyl is
reached in the first microsecond of all replicas, especially in the
inactive receptor state. This is interesting because a recent
report investigating fentanyl binding in MD simulations of the
mMOR failed to obtain a stable binding pose in the inactive
state unless sodium ions (a known negative allosteric
modulator) were co-bound.26 Such ions are not required in
our study. As fentanyl and morphine are both agonists, it might
be expected that they should favor binding of the activated
state over the inactive; however, tight induced-fit of the
activated crystal structure for its co-crystallized morphine-like
agonist BU-725 appears to enable precise docking of morphine
but partially hinders fentanyl. Conversely, the larger size of co-
crystallized antagonist β-FNA in the inactive crystal29 may
favor a faster stabilization of fentanyl in this state compared to
the activated one. Nevertheless, once stable ligand binding is
reached within our MD simulations starting from activated or
inactive states, morphine and fentanyl make different ligand−
receptor interactions. In particular, morphine interacts more
frequently with the N-terminus, TM5, TM6, and TM7, coming
into contact with residues: Asp56N‑ter, Lys2355.39, Ile2986.51,
Val3026.55, Trp3207.35, and Ile3247.39, while fentanyl interacts
with ECL2, TM2, and TM7, coming into contact with
Gln1262.60, Asn1292.63, Val1453.28, Cys219ECL2, and Tyr3287.43.
However, there are similarities as both morphine and fentanyl
interact with Ser57N‑term, Tyr1503.33, and Asp1493.32.
The different molecular scaffolds of morphine and fentanyl
lead to different binding modes, which are associated with
different conformational arrangements in the orthosteric
pocket and which may be related to their different
pharmacological efficacies. The widely described5,7,17,29,30,45
electrostatic interaction with Asp1493.32 has been observed as
essential for binding of μ-opioid ligands, and the Asp1493.32
conformation resulting from it plays a direct role in receptor
(in)activation as shown by mutagenesis experiments.26,48,49
Likewise, H-bonding between Asp1493.32 and Tyr3287.43 in the
orthosteric pocket has been shown to be relevant for MOR
activation.26 Further experimental studies26,46,95 have shown
that Tyr3287.43 has a significant effect on ligand potency and
agonist-induced receptor activation, specifically for fentanyl,
and is conserved and functional in δ- and κ-opioid receptors as
demonstrated by mutagenesis.98 Other mutagenesis studies
have identified Tyr1503.33 to be relevant for agonist binding
affinity,95,97 including fentanyl. In addition, mutation of the
conserved residue Tyr1393.33 in the κ-opioid receptor alters
ligand potency.98 Likewise, a recent mutagenesis study99 has
shown that Cys219ECL2 likely comes into contact with fentanyl
and is relevant in its binding but does not affect receptor
activation. This is an interesting result because it implies a
molecular separation of the affinity and efficacy concepts,
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.0c00890
J. Chem. Inf. Model. 2021, 61, 1251−1274
1266
which is difficult if not impossible to obtain by parameter
estimation from functional studies as the estimated binding
constants in operational models include the receptor activation
component.100 Therefore, our morphine binding pose is in
accordance with previously described binding modes,42,89,90
co-crystallized BU-725 and β-FNA,29 and side-directed muta-
genesis, which determined Val3026.55 or Trp3207.35 to be
crucial for the decrease101 or increase29 of morphine affinity,
respectively. Despite this, to our knowledge, no mutagenesis
studies have been performed for residues: Asp56N‑ter,
Lys2355.39, and Ile3247.39, even though they have been
implicated in morphine binding before.42,90 On the other
hand, the fentanyl binding pose presented in our study, which
presents protein−ligand interactions similar to those shown
previously,25,91 is in agreement with the first point mutation
experiments45,46,97 involving residues Asp1493.32, Tyr1503.33,
and Tyr3287.43 but not Asn1523.35, Trp3207.35, and His3217.36.
As far as we are aware, no experimental mutagenesis has been
performed on Gln1262.60 and Asn1292.63, which we predict to
interact with fentanyl. The relative stability of our observed
binding poses of morphine and fentanyl, irrespective of
receptor conformation, leads us to conclude that they are
sufficiently accurate. As an extra validation of the fentanyl
binding pose, we docked fentanyl to the new DAMGO-bound
fully active crystal structure of the mMOR,30 which might be
expected to yield greater accuracy. This results in a similar
docking pose to that obtained with our hMOR models and
MD simulations (Figure S17), thus adding an extra layer of
confidence.
Conformational dispositions in the orthosteric pocket lead
to alteration of other receptor residues such as Met1533.36 and
Trp2956.48, which assist receptor activation.26,102,103 More
specifically, different conformations of Met1533.36 have been
associated with a specific ligand-dependent microswitch for
MOR β-arresting signaling.25 Although in our results we have
not found multiple active-like states, we observe different
conformations of Met1533.36 more frequently induced when
either fentanyl or morphine is bound into the receptor
orthosteric pocket. In addition, Trp2956.48 has previously been
observed to rotate during activation of the mMOR26,103 and
class A GPCRs, in general,74 and has been commonly named a
“toggle switch”. Such “toggling” can result in different H-
bonding between TM5, TM6, and TM7 and solvation of the
receptor core.26,103 In particular, it has been described that
fentanyl stabilizes different rotameric states of Trp2956.48
compared to morphine or the apo receptor.26 In our study,
we identify ligand-specific orthosteric pocket changes in (i)
ligand interactions with Gln1262.60, Asp1493.32, Tyr1503.33, and
Lys2355.39 including concomitant sidechain rotameric changes,
(ii) interhelical Asp1493.32−Tyr3287.43 H-bonding, (iii) side-
chain rotameric changes in Trp2956.48 and Met1533.36
(influenced by conformational change of Tyr1503.33), and
(iv) proximity and interhelical H-bonding between
Trp2956.48−Ala2425.46 (influenced by conformational change
in Trp2956.48). In terms of how these conformational changes
are connected, we observe that morphine and fentanyl engage
with Asp1493.32 via different gauche− or trans sidechain
conformations, respectively. As trans Asp1493.32 is within the
H-bonding distance with Tyr3287.43, as expected, we find
higher Asp1493.32−Tyr3287.43 H-bond occupancy with bound
fentanyl. Likewise, a trans sidechain conformation of
Gln1262.60, which is induced predominantly when fentanyl is
bound, interacts with Tyr3287.43, further stabilizing
Asp1493.32−Tyr3287.43 H-bonding through a three-way side-
chain interaction thus favoring receptor activation.44,47 In
comparison, the Gln1262.60 cis sidechain conformation,
predominantly selected by morphine, shows lower
Asp1493.32−Tyr3287.43 H-bonding and less favorable receptor
activation.44,47 Differences in Gln1262.60 conformation with
fentanyl and morphine and their influence on Asp1493.32−
Tyr3287.43 H-bonding may partly explain their difference in
efficacy.51−53,56,57 The sidechain conformation of Asp1493.32,
which is dictated by the different binding poses of morphine
and fentanyl, is further dictated by different interactions the
ligands make with Lys2355.39. As both ligands contain an
oxygen acceptor group(s), the sidechain amino group of
Lys2355.39 can theoretically interact with either. In relevant
crystals, Lys2355.39 covalently binds antagonist β-FNA,29 does
not interact with agonist BU-72,5 and makes an H-bond with
agonist DAMGO.30 Differences in the molecular scaffold
between ligands lead to higher Lys2355.39−ligand H-bond
occupancy with bound morphine, which results in different
conformations of Lys2355.39. Accordingly, Lys2355.39−ligand
H-bonding is related to enhanced stabilization of morphine
relative to fentanyl in the orthosteric pocket, thus leading
Asp1493.32 to adopt a gauche− sidechain conformation when
morphine is bound. Therefore, our results indicate that
Asp1493.32−Tyr3287.43 H-bonding, previously described to be
essential for MOR activation,44,47 is determined by ligand
interactions with Asp1493.32 and Gln1262.60 and by its position
in the orthosteric pocket influenced by its interaction with
Lys2355.39.
Oxygen H-bond acceptor groups on morphine and fentanyl
not only establish interactions with TM5 but also make H-
bonds with Tyr1503.33 on TM3, either directly or through a
water molecule. Similar to Lys2355.39, morphine has a higher
Tyr1503.33−ligand H-bond occupancy than fentanyl, which
may enhance TM3 activation and exert a stabilizing effect on
the receptor orthosteric pocket. This includes the crystal
gauche sidechain conformation of Met1533.36, which is largely
induced in simulations starting from the activated state and
when morphine is bound. This conformation stabilizes
hydrophobic interactions that occur at the bottom of the
orthosteric pocket restricting the transition from one state to
the other. In this respect, signal transmission along TM3 from
Tyr1503.33 to Met1533.36 of the hMOR is similar to that of
other GPCRs such as the nociceptin receptor.102 On the
contrary, selection of the Met1533.36 trans conformation by
fentanyl when the receptor is in an inactive-like state suggests a
destabilization of the hydrophobic interactions, which supports
transition from an inactive receptor state to a more active one
by disconnecting TM3 from TM6. These results indicate that
fentanyl has a facility to change Met1533.36 from an inactive to
active-like conformation more frequently than morphine. In
addition to Asp1493.32−Tyr3287.43 and Tyr1503.33−ligand H-
bonding and associated conformational change of Met1533.36,
the conformational toggling of Trp2956.48 has previously been
described in the activation of the MOR26 and δ-opioid
receptor.104 The Trp2956.48 sidechain also adopts different
conformations in inactive,29 activated,5 and fully active crystals
of the mMOR.30 In our MD simulations with either bound
morphine or fentanyl, Trp2956.48 adopts an inactive-like gauche
or an activated-like trans conformation depending on the
receptor state and ligand bound. The trans position resembles
the conformation observed in the fully active crystal
structure,30 adopting a perpendicular orientation to TM6 but
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with the indole NH pointing toward TM5 instead of TM7.
This conformation is in general agreement with a recent study
implementing MD simulations of the mMOR with docked
fentanyl but differs from those observed with docked
morphine.26 The reason for this discrepancy over morphine
is unclear but could be due to differences between mouse and
human receptor models or co-bound sodium ions, which might
negate agonist activity.26 In our simulations starting from the
inactive hMOR, the trans conformation of Trp2956.48 is only
obtained twice, once with bound morphine and the other more
transiently with fentanyl. This shows that activation of the
hMOR, in particular TM6 conformational change, is a
relatively difficult process to capture in a microsecond period.
This contrasts with the relative ease of receptor activation
observed in MD simulations of other class A GPCRs, such as
CB177 or adenosine A2A.78 In some respects, this fits with the
low constitutive activity displayed by the hMOR in
pharmacological experiments,85 which suggests a highly stable
inactive state. When Trp2956.48 adopts the trans conformation,
it allows interhelical H-bonding with Ala2425.46, a position
which has been shown to be relevant for TM5 flexibility in
class A GPCRs.81 Conversely, the gauche conformation of
Trp2956.48 H-bonds Asn3307.45 when whole TM6 movement is
not present and the distance between Trp2956.48 and Ala2425.46
is large. As a result, conformational change and activation of
TM5 and TM6 are highly related to close Trp2956.48−
Ala2425.46 interaction, either by H-bond formation or helical
rearrangement. Together with Asp1493.32−Tyr3287.43 and
Tyr1503.33−ligand H-bonding, as well as Met1533.36 conforma-
tional change in the receptor orthosteric pocket, these are the
factors that most strongly govern intracellular receptor
conformation and where differences between morphine and
fentanyl are most clear.
In our MD simulations, conformational changes of TM
helices differently occur with bound morphine or fentanyl.
While morphine largely induces or selects conformational
activation changes of TM3 and TM5, fentanyl more frequently
achieved active-like conformations of TM6 and TM7.
Conformational rearrangements of these TM helices are
reflected in changes in specific intracellular regions such as
Arg1673.50−Thr2816.34 interaction between TM3 and TM6
and the NPxxY motif on TM7. However, in the most part, we
observe that the distance between Arg1673.50 and Thr2816.34
and conformation of the NPxxY motif remain constant when
the receptor is already in the activated state with bound
fentanyl or morphine, which means that both agonists
generally sustain the active receptor state, which is consistent
with their agonist character. However, activation of the
receptor from the inactive state through breakage of
Arg1673.50−Thr2816.34 interaction and conformational change
of the NPxxY motif is more frequently observed with bound
fentanyl than with morphine. This suggests that fentanyl more
strongly induces conformational changes in the NPxxY motif
through enhanced Asp1493.32−Tyr3287.43 H-bonding and
enables TM3−TM6 separation through disruption of
Met1533.36 conformation and Trp2956.48−Ala2425.46 transient
H-bonding and further close contact. This may be indicative of
its higher efficacy observed at the experimental level51−53 and
also reflects the allosteric communication that operates
between the orthosteric pocket and intracellular regions of
the hMOR. Nearly all orthosteric metrics analyzed in this study
have shown statistically significant association with the state of
intracellular metrics studied, independent of the ligand bound
and receptor starting state. This communication has been
proposed to operate, at least in part, through a polar network
mediated by water molecules, which changes depending on the
receptor state.5,79−81 Here, we have identified two water
clusters, which differ between active- and inactive-like states or
between morphine/fentanyl bound systems: (i) intracellular
solvation near the NPxxY region on TM7 and (ii) solvation in
the receptor core between Asn3307.45 and Trp2956.48. In
particular, the former has been described to occur during
activation of the hMOR and class A GPCRs in general.5,53,81
This is partly because TM6 conformational change involved in
the transition from the inactive to near-active receptor state, as
observed more with bound fentanyl, leads to greater solvation
in intracellular receptor regions, including the NPxxY motif, as
well as the receptor core near Trp2956.48. On the contrary, the
smaller size of morphine allows greater solvation of the
orthosteric pocket, which may negatively affect its binding
stability in the inactive receptor state. Furthermore, the
energetic state of these waters and how fentanyl potentially
displaces more of them in the orthosteric pocket relative to
morphine can be the topic of future study.
In summary, our dynamics of the hMOR are determined by
ligand binding to activated5 and inactive29 receptor models,
based on mMOR crystal structures, including extracellular/
intracellular loops and modeled N-termini. The recently
published fully active mMOR cryo-EM structure30 allows for
an independent positive control of MD-generated receptor
structures. In addition, MD simulations with the antagonist
naltrexone bound represent a negative control that allows us to
better describe differences between fentanyl and morphine.
Likewise, the constitution of the geometry of our hMOR
models is validated by the mutual ligand and receptor
conformational stability in control systems with BU-72 or
naltrexone bound, respectively, to activated or inactive states.
Two different physically stable binding poses of morphine and
fentanyl in the hMOR mediate different sets of protein−ligand
interactions (in particular involving Gln1262.60, Lys2355.39,
Asp1493.32, Lys2355.39, and Tyr1503.33), which differentially
change orthosteric pocket conformation (in particular
Asp1493.32−Tyr3287.43 H-bonding, Met1533.36 orientation,
and Trp2956.48−Ala2425.46 interaction). These result in
different intracellular TM3, TM5, TM6, and TM7 conforma-
tional changes, including movement of the NPxxY motif and
Arg1673.50−Thr2816.34 separation. Fentanyl has a stronger
effect on TM6 and TM7 conformation, while morphine
preferentially affects TM3 and TM5. As conformational change
in TM6 is critical for GPCR activation and G protein binding
in particular, this likely explains the enhanced receptor activity
elicited by fentanyl in vivo, which has 50−100-fold higher
potency than morphine.51−53,56,57 The structural insights
gained in the present study can be used in future work with
a spread of μ-opioid targeting drugs, to identify those
interactions and conformational changes associated with
particular ligand efficacy and the disjunction between signaling
networks through the receptor, which probably determine the
proficiency in modulation of the receptor intracellular pocket
and Gi protein or β-arrestin recognition.
■ METHODS
Homology Modeling. The crystal structures of activated
and inactive states of the mMOR (PDB ids: 5C1M5 and
4DKL29) were used to model respective hMOR states using
Chimera v1.11105 and Modeller v9.16.106 Non-native camelid
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G protein mimetic nanobody Nb39 and T4L lysozyme fusion
protein were removed from respective activated5 and inactive29
mMOR crystal structures, as well as co-crystallized opioids:
BU-725 and β-FNA,29 respectively. In order to homology
model human wt-sequence (Uniprot ID: P35372)107 hMOR
models, respective activated5 and inactive29 mMOR crystal
structures were used as templates and with renumbered
sequences, so Gly52 was renumbered to Gly54, and so. Using
Chimera105 and the Dunbrack 2010 rotamer library,108
sidechain modifications were performed on S55R, H56D,
Q61P, V68I, N139T, V189I, and I308V, which correspond to
nonconserved residues between species. The most probable
rotamer with the fewest steric clashes was chosen in each
instance. Using Modeller,106 noncrystallized segments of the
inactive hMOR N-terminus (residues Gly54 to Ile73), inactive
hMOR intracellular loop 3 (ICL3; residues Val264 to Lys271),
and activated hMOR C-terminus (residues Arg347 to Ile354)
were homology modeled using the other receptor structure as a
template. Subsequently, activated and inactive hMOR models
were energy-minimized in the AMBER14SB force-field109
using Chimera in vacuum conditions105 to optimize internal
interactions.
Ligand Docking. The structures of three ligands of interest
for the present study, morphine and fentanyl, and negative
control naltrexone, were extracted from Pubchem110 and
docked in activated and inactive hMOR models using
Autodock4.2.6.111 Specifically, morphine, fentanyl, and nal-
trexone were prepared by respectively selecting their bioactive
isomer, protonating their amino group (consistent with
physiological pH), and assigning a net charge of +1 in order
to correctly interact with Asp1493.32. This particular protein−
ligand interaction is in accordance with co-crystallized μ-opioid
agonists (BU-72; DAMGO),5,30 antagonist (β-FNA),29 and
related structural data.91 In addition to the naltrexone-bound
inactive state of the hMOR, for control purposes, co-
crystallized BU-72 was re-docked into the activated hMOR
state with its amino group protonated as other ligands.
Docking grid points were extended to cover total orthosteric
pocket volumes, respectively. The selected docked conforma-
tion of each ligand in each receptor state represents the top hit
identified by the best predicted affinity, which also makes
correct interaction with Asp1493.32. Subsequent docked
ligand−receptor complexes were energy-minimized in the
AMBER14SB force-field109 using Chimera105 in vacuum
conditions to optimize protein−ligand interactions.
MD System Setup. Two control systems, BU-72 bound to
the activated hMOR and naltrexone bound to the inactive
hMOR, and five different systems of interest were generated:
morphine-bound activated and inactive hMOR, fentanyl-
bound activated and inactive hMOR, and naltrexone-bound
activated hMOR; each embedded separately into a POPC
membrane using the CHARMM-GUI web-based interface112
and solvated with TIP3P water molecules. All models were
oriented in the membrane according to the OPM database113
entry of the activated mMOR (id: 5c1m).5 The disulfide
bridge between Cys1423.25 and Cys219ECL2 was maintained in
all systems, and charge neutralizing ions (0.15 M KCl) were
automatically introduced in order to make a net system charge
of 0. CHARMM-GUI112 automatically generated membrane,
water, and protein parameters according to the CHARMM36
force-field114 and ligand parameters in accordance with
CHARMM General Force Field (CGenFF) v.1.0.0.115
MD Simulations. MD simulations of each hMOR system
starting from either activated or inactive states with bound
morphine, fentanyl, or naltrexone were performed in triplicate
using the CHARMM36 force-field114 with ACEMD116 on
specialized GPU-computer hardware. Each replica was energy-
minimized for 2000 steps followed by 28 ns of equilibration at
300 K and 1 atm, with positional harmonic restraints on
protein and ligand heavy atoms progressively released over the
first 8 ns of equilibration and thereafter continued without
restraints. This was followed with an unbiased continuous
production run under the same conditions for 3 μs for each
replica. In addition, the control hMOR system with bound BU-
72 was run in duplicate for 2 μs after the same energy-
minimization and equilibration process as systems of interest,
making a total additive simulation time of 58 μs.
MD Simulation Analysis. In order to evaluate activated
and inactive hMOR model accuracy, we respectively analyzed
the conformational stability of the receptor helical domain and
co-crystallized ligand BU72 or naltrexone (substituted for co-
crystallized β-FNA) making use of RMSD measurements with
VMD software v1.9.2.117 Analysis of the three microseconds of
each trajectory with bound morphine, fentanyl, or naltrexone
(including control replicas of the naltrexone-bound inactive
state) was performed using VMD117 with the following
protocol: (i) ligand stability in inactive and activated hMOR
models and (ii) analysis of respective stable binding poses; (iii)
comparison between ligand-mediated hMOR orthosteric
pocket conformational changes and their correlation with
(iv) TM helical movement; (v) intracellular receptor
conformational state and (vi) conformational changes of the
rest of the receptor; (vii) water-network differences associated
with different receptor states. Evaluation of conformational
stability was measured by the analysis of the two last
microseconds of each replica of the systems generated,
whereas residue-specific conformational changes were studied
considering the entire simulation time-period. In detail, RMSD
measurements of fentanyl or morphine in their respective MD
simulations were used to monitor ligand stability. In addition,
all fentanyl, morphine, and naltrexone conformations achieved
during respective trajectories were classified into five different
clusters using a cutoff of 2.0 Å using VMD Clustering Tool.117
A list of residues that came into contact with either morphine
or fentanyl (<3.5 Å) in each replica of each system and their
frequency were extracted making use of a smoothing/averaging
TCL script118 executed in VMD.117 Electrostatic, van der
Waals, and hydrophobic interactions between the ligand and
residues with frequencies ≥20.0% in two or more replicas were
analyzed for energetics using NAMD Energy plugin119 v1.4
within VMD.117 RMSD analysis of the hMOR TM domain was
performed with respect to respective receptor starting
conformation or with the fully active crystal30 to assess
receptor stability or (in)activation. A threshold of ± 3.5 Å from
the initial receptor state as well as activated and inactive crystal
conformational divergence from fully active crystal30 was used
to determine significant receptor conformational changes.
Intracellular receptor conformational changes associated with
activation/deactivation were analyzed by making use of
VMD117 in terms of movement with respect to the protein
center of (i) TM3, (ii) the intracellular tip of TM5, (iii) the
intracellular tip of TM6, and (iv) the NPxxY motif on TM7, in
addition to (v) distance measurement between alpha carbons
of residues Arg1673.50 and Thr2816.34. TM3 upward axial
movement was measured by z axis offset difference between
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TM3 and the protein center of mass (COM). Helix tips were
defined according to the second and third-last intracellular
helical turns (TM5: residues 251−261, TM6: 274−284) and
distances measured relative to the protein COM. Taking in
consideration differences between crystal structures5,29,30 in
their positions of TM3, TM5, and TM6 as well as MD
simulations with the antagonist naltrexone bound, relevant
internal distances measured were normalized with respect to
the inactive crystal,29 with respective distance thresholds of
+0.3, −0.8, and + 1.7 Å used to classify active or inactive helix
conformations. Active- or inactive-like conformations of
intracellular metrics such as the NPxxY motif and
Arg1673.50−Thr2816.34 interaction were defined by distance
from the protein COM (using −0.8 Å threshold) or by +10.0
Å for Arg1673.50−Thr2816.34 inter-residue distance. Residues
showing differences in their P.E. of interaction between bound
fentanyl and morphine were analyzed according to (i)
sidechain χ1 dihedral angle; (ii) χ2 dihedral angle; (iii) P.E.
of interaction with nearby residues; (iv) distribution with
respect to conformational changes of other residues; and (v)
correlation with intracellular receptor conformational changes.
Sidechain dihedral angles were classified according to a
threshold between predominantly observed χ1 and χ2 dihedral
angle conformations. Thus, a ± 115.0° value was used as a
threshold for classifying Asp1493.32 χ1 dihedral angle
conformation (gauche and trans conformations), ± 90.0°
threshold for the Met1533.36 χ1 dihedral angle (gauche or
alternative conformations), and ± 240.0° threshold for
Lys2355.39 and Gln1262.60 χ2 dihedral angles (predominant
cis and trans conformations of 300.0° and 180.0°, respectively).
Electrostatic intersidechain or ligand−sidechain interactions
were specified according to ± 4.5 Å distance threshold. H-
bonding between morphine, fentanyl, or naltrexone with
Asp1493.32 was selected according to a threshold of ± 2.5 Å.
Distances/H-bonding was measured between (i) fentanyl,
morphine, or naltrexone amino groups and Asp1493.32 gamma
carbon (considered as the center of the Asp1493.32 carboxylate
group), (ii) fentanyl, morphine, or naltrexone oxygen accept-
or/donor atoms (a single carbonyl group in the former or one
ether and two hydroxyl groups in morphine or one ether, one
hydroxyl group and one carbonyl group in naltrexone) and the
Tyr1503.33 hydroxyl group or the Lys2355.39 amino group, (iii)
Asp1493.32 gamma carbon and the Tyr3287.43 hydroxyl group,
and (iv) the Trp2956.48 indole NH group and the Ala2425.46
backbone carbonyl group. Distance between residues
Trp2956.48 and Ala2425.46 was measured between their
respective sidechain COMs. Water density maps were created
using VolMap within VMD117 by calculating the weighted
atomic density of water molecules averaged over the last two
microseconds of each MD replica.
Statistical Analysis. Chi-square (Chi2) and Student’s t-
test statistical analyses were performed to assess the statistical
significance of the potential association between orthosteric
pocket metrics (sidechain−sidechain Asp1493.32−Tyr3287.43,
Tyr1503.33−ligand, Lys2355.39−ligand, and sidechain−back-
bone Trp2956.48−Ala2425.46 H-bond presence or absence,
Met1533.36 gauche conformation selection, or Trp2956.48−
Ala2425.46 distance, respectively) with the intracellular
conformations achieved (active- or inactive-like conformation
of TM3, TM5, TM6, NPxxY, and Arg1673.50−Thr2816.34
distance). To perform these analyses, we used 50 representa-
tive snapshots of each replica, extracted every 40 ns of the last
two microseconds of respective trajectories, independent of the
initial state of the receptor or the ligand bound, thus making a
total sample of 900 receptor−ligand conformations. This
sample was considered sufficient to construct two-way
contingency tables to evaluate the Chi2 score and to perform
Student’s t-test analysis for exploring general mechanistic
trends. P < 0.05 was considered statistically significant. IBM
SPSS Statistics 20.0.0 was used for statistical analyses.
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(77) Díaz, Ó.; Dalton, J. A. R.; Giraldo, J. Revealing the mechanism
of agonist-mediated cannabinoid receptor 1 (CB1) activation and
phospholipid-mediated allosteric modulation. J. Med. Chem. 2019, 62,
5638−5654.
(78) Bruzzese, A.; Dalton, J. A. R.; Giraldo, J. Insights into adenosine
A2A receptor activation through cooperative modulation of agonist
and allosteric lipid interactions. PLoS Comput. Biol. 2020, 16,
No. e1007818.
(79) Yuan, S.; Filipek, S.; Palczewski, K.; Vogel, H. Activation of G
protein-coupled receptors correlates with the formation of a
continuous internal water pathway. Nat. Commun. 2014, 5, 1−10.
(80) Tomobe, K.; Yamamoto, E.; Kholmurodov, K.; Yasuoka, K.
Water permeation through the internal water pathway in activated
GPCR rhodopsin. PLoS One 2017, 12, 1−14.
(81) Venkatakrishnan, A. J.; Ma, A. K.; Fonseca, R.; Latorraca, N. R.;
Kelly, B.; Betz, R. M.; Asawa, C.; Kobilka, B. K.; Dror, R. O. Diverse
GPCRs exhibit conserved water networks for stabilization and
activation. Proc. Natl. Acad. Sci. U. S. A. 2019, 116, 3288−3293.
(82) Kaya, A. I.; Perry, N. A.; Gurevich, V. V.; Iverson, T. M.
Phosphorylation barcode-dependent signal bias of the dopamine D1
receptor. Proc. Natl. Acad. Sci. U. S. A. 2020, 117, 14139−14149.
(83) Celver, J. P.; Lowe, J.; Kovoor, A.; Gurevich, V. V.; Chavkin, C.
Threonine 180 is required for G protein-coupled receptor kinase 3-
and beta-arrestin 2-mediated desensitization of the mu-opioid
receptor in Xenopus oocytes. J. Biol. Chem. 2001, 276, 4894−4900.
(84) Zhou, B.; Hall, D. A.; Giraldo, J. Can Adding Constitutive
Receptor Activity Redefine Biased Signaling Quantification? Trends
Pharmacol. Sci. 2019, 40, 156−160.
(85) Seifert, R.; Wenzel-Seifert, K. Constitutive activity of G protein-
coupled receptors: cause of disease and common property of wild-
type receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2002, 366,
381−416.
(86) Söldner, C. A.; Horn, A. H. C.; Sticht, H. A Metadynamics-
Based Protocol for the Determination of GPCR-Ligand Binding
Modes. Int. J. Mol. Sci. 2019, 20, 1970.
(87) Bruzzese, A.; Dalton, J. A. R.; Giraldo, J. Statistics for the
analysis of molecular dynamics simulations: providing P values for
agonist-dependent GPCR activation. Sci. Rep. 2020, 10, 19942.
(88) Bruzzese, A.; Gil, C.; Dalton, J. A. R.; Giraldo, J. Structural
insights into positive and negative allosteric regulation of a G protein-
coupled receptor through protein-lipid interactions. Sci. Rep. 2018, 8,
4456.
(89) Serohijos, A. W.; Yin, S.; Ding, F.; Gauthier, J.; Gibson, D. G.;
Maixner, W.; Dokholyan, N. V.; Diatchenko, L. Structural basis for
mu-opioid receptor binding and activation. Structure 2011, 19, 1683−
1690.
(90) Berríos-Cárcamo, P.; Quintanilla, M. E.; Herrera-Marschitz, M.;
Vasiliou, V.; Zapata-Torres, G.; Rivera-Meza, M. Racemic Salsolinol
and its enantiomers act as agonists of the μ-Opioid receptor by
activating the Gi protein-adenylate cyclase pathway. Front. Behav.
Neurosci. 2017, 10, 253.
(91) Spahn, V.; Del Vecchio, G.; Labuz, D.; Rodriguez-
Gaztelumendi, A.; Massaly, N.; Temp, J.; Durmaz, V.; Sabri, P.;
Reidelbach, M.; Machelska, H.; Weber, M.; Stein, C. A nontoxic pain
killer designed by modeling of pathological receptor conformations.
Science 2017, 355, 966−969.
(92) Subramanian, G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson,
D. M. Molecular docking reveals a novel binding site model for
fentanyl at the μ-opioid receptor. J. Med. Chem. 2000, 43, 381−391.
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